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“One of the advantages of being disorderly is that one is constantly making  
exciting discoveries.” 
– A. A. Milne (author of Winnie-the-Pooh) 
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ABSTRACT 
Malignant mesothelioma is an asbestos induced cancer that is difficult to diagnose. 
Several studies have combined biomarkers to improve mesothelioma diagnosis, but 
with moderate success, and there is a need for new mesothelioma biomarkers. The 
tumour is often resistant to treatment and most patients will survive less than a year. 
An indicator of patient survival is the tumours growth pattern, which in turn is 
influenced by expressed proteoglycans. 
 
In this thesis work, we aim to improve the possibilities to diagnose malignant 
mesothelioma by combining biomarkers and by identifying new ones. We also 
investigate tumour driving mechanisms with focus on one of these suggested 
biomarkers, the cell-bound proteoglycan syndecan-1. 
 
We were able to construct a diagnostic two-step model based on biomarkers in patient 
material. By implementing a cut-off level and thereafter focusing on unresolved patients 
we combined hyaluronan and N-ERC/mesothelin (paper I), which significantly increased 
the diagnostic accuracy for malignant mesothelioma. To further improve diagnosis, we 
used mass spectrometry to find new biomarkers. We identified and validated galectin-1, 
which was excellent in discriminating mesotheliomas from adenocarcinomas (paper II). 
In the same study, we were also the first to describe aldo-keto reductase 1B10 as a 
novel prognostic mesothelioma biomarker. 
 
Syndecan-1 has been indicated as a marker for carcinomas. In paper I we describe how 
higher levels of syndecan-1 indicate the presence of a carcinoma over a mesothelioma. 
This was verified in paper II when syndecan-1 was identified as downregulated in fluids 
from mesothelioma patients compared to lung cancer patients. Paper III and paper IV 
focus on this proteoglycan. 
Malignant cell lines transfected with syndecan-1 and various truncated forms of 
syndecan-1 affected adhesion and migration, which are key features of cancer invasion 
(paper III). The results showed a domain- and cell type specific effect on the cells’ 
motility. Regulating syndecan-1 levels and analysing the global gene expression of 
mesothelioma cells made it evident that this proteoglycan has a strong influence on 
transforming growth factor β signalling and several growth factor pathways (paper IV). 
Links to cell migration and proliferation were furthermore identified, along with 
glycosaminoglycan modifying enzymes. These results can shed light on the complex role 
of syndecan-1 in invasion and growth of malignant mesenchymal cells. 
 
Taken together, this thesis work describes a complement to conventional mesothelioma 
diagnosis and identifies novel biomarkers. Furthermore, the potential biomarker 
syndecan-1 was shown to have an effect on cell motility and proliferation. These results 
increase our understanding of this aggressive malignancy. 
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1 BACKGROUND 
1.1  THE HALLMARKS OF CANCER AND TUMOUR HETEROGENEITY 
Cancer is a collective term for around 200 different diagnoses. In 2008 there were 12.7 
million new cancers diagnosed globally, and 7.6 million people would die due to their 
cancer in the same year5. A recent review6 summarised the growing framework of the 
disease – a conceptualisation that is a work in progress and describing cancer as an 
intricate society with a limited set of underlying hallmarks. 
 
Even when a cancer arises from mutations in a single cell, the resulting tumour is a 
mixture of several different malignant cell populations7. The resulting heterogeneity is 
illustrated in a set of studies that sequenced the genome of several cancer types and 
identified a large amount of mutations8-10. Surprisingly, the majority of the mutations do 
not overlap with another cancer from the same origin and between tumour types the 
overlap is virtually non-existing. So how is it that different proliferative malignant 
diseases can be described using only a handful of common hallmarks6 if so few of the 
mutations are shared? It seems that even though the overlap of mutated genes 
between tumours is very small, the pathways they influence are very similar10. In other 
words, the driving mutations might vary between tumours, but the effects these 
mutations have will overlap. This high degree of heterogeneity, still with adherence to 
characteristic pathways is also encountered in malignant mesothelioma and will affect 
our interpretation of the disease when aiming for diagnoses, therapeutic measures and 
prognosis. 
 
1.2  MALIGNANT MESOTHELIOMA 
Malignant mesothelioma is a rare but highly aggressive tumour. The mortality is one of 
the highest associated with cancers11. Since the mesothelial tissues arise from 
mesoderm and commonly express neural cell adhesion molecule (NCAM), this 
malignancy is classified as a sarcoma, however, often with epithelial resemblance. There 
are two major localizations of malignant mesothelioma: the pleura and peritoneum12. 
Malignant mesothelioma may also arise in the pericardium12 or tunica vaginalis testis13. 
This thesis regards the pleural form of malignant mesothelioma. 
 
1.2.1 The pleura 
Each lung is covered by a thin mesenchymal tissue, the pleura, which also covers the 
chest wall. The pleural tissue covering the lungs is the visceral pleura and the layer lining 
the chest is the parietal pleura. The cells in this tissue originate from the mesoderm, but 
resemble epithelium by covering a surface in an epithelial-like manner, hence the word 
mesothelium.14 The entire pleural tissue consists of a single layer mesothelium resting 
on a basal membrane with underlying connective tissue. The mesothelial cells have a 
flattened shape with a distinct epithelioid phenotype and often a multitude of apical 
microvilli, which are a distinct attribute14,15. The connective tissue is intersected with 
lymphatic vessels, blood vessels, immune cells and fibroblast-like cells. It has been 
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shown that fibroblast-like cells can differentiate and replace the damaged mesothelium 
following injury14,16. 
 In the pleural cavity between the two layers there is a small amount of fluid for 
lubrication that minimises friction between the visceral and parietal layers during 
breathing. Usually the serous fluid is less than a few millilitres in an average sized 
body.14 This fluid is continuously circulating, from the intercostal arteries, partly 
produced by the mesothelial cells and then drained into the lymphatic circulation17. 
 Apart from facilitating relatively frictionless movement between the chest wall and the 
lungs, the pleural mesothelium also controls additional tissue functions. These include 
trans-membrane material flux, regulation of fibrinolysis, maintenance of serosal integrity 
by producing growth factors (GF) and extracellular matrix (ECM) components. The pleura 
also aid leukocyte migration to sites of inflammation, synthesis of cytokines and 
inflammatory mediators as well as contributing to antigen presentation. Among the most 
common growth factors found in the pleural space are transforming growth factor β 
(TGFβ), platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), vascular 
endothelial growth factor (VEGF), hepatocyte growth factor (HGF; scatter factor) and 
heparin-binding epidermal growth factor-like growth factor. Common cytokines and 
chemokines include interleukins (IL) 1, IL6, IL8 and IL15; prostaglandins and SDF-1.14 
 
1.2.2 Pathological conditions of the pleura 
The pleura encounter many carcinogens and pathogens that cause various cellular 
injuries. Infections and inflammation are common and pose challenges in diagnosis and 
treatment.18 Long-term inhalation of several industrial and natural fibres causes chronic 
inflammation and scarring of the pleura. Inflammation and injury result in cellular 
responses both from the immune system and the mesothelium itself. 
 
Cancers in the pleural cavity are most often metastatic adenocarcinomas from other 
organs19, but there are also tumours arising from the pleural tissue. Solitary fibrous 
tumours of the pleura are mostly benign mesenchymal tumours without the typical 
mesothelial immunophenotype, and if diagnosed early total resection results in a 97 per 
cent 5-year survival. Prognosis becomes quickly poor if re-resection is necessary or 
malignant transformation has occurred. This tumour can be difficult to distinguish from 
the most common primary malignancy of pleural origin, the malignant pleural 
mesothelioma.20 
 
1.2.3 Malignant pleural mesothelioma  
The pleural form of malignant mesothelioma is the most common type accounting for 
more than 70 per cent of all mesothelioma cases12,21. 
 
1.2.3.1 Epidemiology 
Incidence, latency, survival and mortality  
The best known causative agent for mesothelioma is asbestos (see section Asbestos, 
under 1.2.3.2) and even though the relationship between asbestos and mesothelioma 
has been known for over half a century and asbestos usage is banned in a large part of 
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FIGURE 1. Incidence of malignant mesothelioma in 
Sweden, with the incidence of women (grey shaded line) 
and men (line) in Sweden between the years 1970 and 
2010. The initial steep increase is most likely caused by an 
equal increase in awareness of the diagnosis. Incidence data 
was extracted from the Swedish National Cancer Register. 
the world, the malignant mesothelioma incidence is still increasing globally22. In 2010, 
Australia was reported to have the world’s highest national incidence of malignant 
mesothelioma at circa 35 cases per million inhabitants23. In the United States the 
incidence ranges between 20 and 25 per million for men and around 2 per million for 
women. The incidence might already have peaked in the United States24, but in the 
United Kingdom the incidence is expected to reach its peak in 201525. 
 Sweden has seen a steady increase of mesothelioma cases per year since the 1970s 
(figure 1). A large part of this increase can be linked to improved diagnosis, which is 
probably true for all reported estimates. The incidence in Sweden is approx. 10 per 
million for men and 1 to 2 per million for women (data extracted from the Swedish 
National Cancer Registry). The difference between the sexes is due to the work-related 
exposure to asbestos. There is, however, also a non-asbestos induced malignant 
mesothelioma representing a constant background prevalence of the disease26. 
 
The latency period between 
asbestos encounter and first 
clinical symptoms is usually 
longer than 20 years12, not 
uncommonly up to 40 years or 
longer27. This characteristically 
long time is a contributing factor 
to the continued rise in the 
incidence of the disease – even in 
countries that have long 
restricted usage of asbestos. The 
median age of diagnosis has been 
reported to be between 72 and 74 years12,21 which is in line with work-related exposure 
to asbestos and a long latency period. The lifetime risk of malignant mesothelioma 
persists, even after exposure has ceased28,29. This is the opposite of individuals who stop 
smoking and decrease their lung cancer risk over the following years. 
 
Malignant mesothelioma is a fatal disease and patients have an overall median survival 
of between 9 and 12 months22. Tumour stage does not seem to be a good predictor of 
survival and survival itself has not improved significantly over the last few decades21. 
Five-year survival for malignant mesothelioma is a gloomy 9 per cent30, although some 
individuals may survive for 10 years or more.  
 
Malignant mesothelioma has been called a man-made disease and its slow but 
widespread increase in occurrence has been described as an epidemic. Without doubt, 
malignant mesothelioma has a tremendous socio-economic and political effect on 
society. The economic impact of asbestos related lung cancers and malignant 
mesothelioma is estimated to be three times higher than the revenue of asbestos 
trade31. Company litigations alone are estimated to cost a staggering 300 billion USD in 
the western world in the next few decades32. Additional costs of asbestos removal and 
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associated administration adds to malignant mesothelioma being regarded as one of the 
world’s worst industrial accidents. In the 1970s the USA Occupational Safety and Health 
Administration initiated a screening program to identify individuals in need of 
treatment. The program used chest X-ray, health history and spirometry, but showed 
poor ability to predict a malignant mesothelioma33. 
 
1.2.3.2 Aetiology 
Asbestos 
Asbestos is by far the most common causative agent for malignant mesothelioma34-36, 
with 80 per cent of mesothelioma patients reporting asbestos exposure27. As well, 
mesothelioma is the primary malignancy resulting from asbestos exposure30 with 5 to 10 
per cent of heavily asbestos exposed individuals developing the disease11. The 
relationship between asbestos and malignant mesothelioma was described for the first 
time in South African miners by Wagner et al. in 196037. This relationship is one of the 
clearest between a carcinogen and its associated cancer. 
 
Asbestos is a group of hydrated fibrous silicate minerals that occur in nature and comes 
in two major groups: serpentines, including chrysotile (white asbestos; figure 2a) and 
the amphiboles, including crocidolite (blue asbestos; figure 2a) and amosite (brown 
asbestos)36. While white asbestos comprises 90 per cent of the world’s entire asbestos 
consumption38, blue asbestos is the most carcinogenic form39. There has been a long 
standing debate whether the white form leads to malignant mesothelioma or not39. 
However, exposure to white asbestos predisposes individuals to smoking-induced 
bronchogenic lung cancers38 and there is evidence showing an increased overall cancer 
incidence34 and mortality in exposed cohorts40. It should also be cautioned that white 
asbestos can be contaminated with blue asbestos. 
 
The word asbestos is Greek and means unquenchable; it is naturally formed over 
millennia under high pressure and in the right chemical milieu41. The properties of 
asbestos have been known for thousands of years. Due to its remarkable heat-resistant 
capacities asbestos has been called a miracle-fibre and been extensively used in 
industry42 (it has even been thought to defeat superheroes: see box 1). Hence, asbestos 
has been widely used as insulation and fire-protection in plumbing, cars and houses 
(figure 2b). The people most exposed to this carcinogen are therefore asbestos miners, 
shipyard workers, plumbers, electricians, construction workers and people in similar 
professions21,22,43,44. The commercial use of asbestos peaked between 1930 and 196043, 
but asbestos has been banned, or strongly restricted, in several countries since then45. 
Still, due to its low cost – at least in the short term – many countries import and 
consume asbestos even today46,47. Restrictions of asbestos in the western world has not 
deterred an increase in its sale and usage in developing countries48, possibly foretelling 
of yet another mesothelioma epidemic to come. 
 
There are also some natural deposits of asbestos and asbestos-like minerals, around the 
world that can lead to unprovoked asbestos exposure. A Japanese study analysed 
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FIGURE 2. Asbestos and malignant mesothelioma. 
a) Left side is chrysotile (white asbestos); its soft 
appearance is contrasted against the sharp nature of 
the crocidolite form (blue asbestos; right side)
1
. Bar 
is 50 micrometres. Images are from scanning 
electron microscopy. b) A house with typical 
asbestos panels covering a majority of the outside. 
These panels contain approx. 10 per cent white 
asbestos, which is harmless if left undisturbed. The 
house is the author’s childhood home. c) A light 
microscopy image of an asbestos fibre recovered 
from sputum. Iron deposits can be seen along the 
entire fibre (a ferruginous body), especially 
pronounced at its ends. Micrograph kindly provided 
by Prof. em. A. Hjerpe. d) A computed tomography 
scan shows a cross section of the thorax of a 
mesothelioma patient. The left lung (right side of 
image) is encompassed by a malignant pleural 
mesothelioma. Case contributed by: Dr F. Gaillard
2
. 
All images are reprinted under a CC licence. 
hundreds of air samples from all over the country and identified asbestos (chrysotile) in 
almost all of them. The study also detected amounts in samples from a serene island in 
the Pacific Ocean and ice cores from Antarctica, suggesting a universal exposure49.  
 
In the Cappadocia region of Turkey 
there is an asbestos-like mineral 
occurring naturally. This fibre, named 
erionite, is believed to be even more 
carcinogenic than asbestos and is 
strongly linked to mesothelioma50. 
Erionite containing rocks are used to 
build houses in certain villages and 
the mineral itself produces a white 
powder that is a popular component 
of indoor paint. This environmental 
and domestic exposure has led to a 
much higher incidence of mesotheli-
oma in these settings compared to for 
example Sweden51. The incidence is 
not only drastically higher but with 
the different exposure in the domestic 
environment the risk is also 
differentially distributed between the 
sexes. Reports are not uncommon 
with erionite exposure where more 
than half the studied mesothelioma 
patients were women52. Studies in 
Sweden, the Netherlands and USA 
report a low incidence in women44,53. 
In some of these Turkish villages 
erionite has caused mesothelioma in 
half the population, also affecting 
younger people than would be expected26,50. Extremely high incidence rates are 
fortunately very rare, but have also been reported in the Australian mining community 
of Wittenoom29, one of the world’s few blue asbestos mining communities. 
Wittenoom’s mine closed in 1966 due to unprofitability and growing health concerns, 
and the entire town was officially abolished by the Australian government in 2007. 
 
Asbestos fibres of a certain length and width are inhaled all the way out to the alveoli 
where they lodge in the lung tissue. Over time, these fibres migrate out to both layers of 
the pleura. Fibre presence is evident from tissue samples containing encapsulated 
asbestos fibres.54 These fibres are like thin spears that can penetrate plasma 
membranes without killing the cells. During mitosis the asbestos fibres can cause 
aberrant karyotypes with possible malignant outcome. Furthermore, upon attempted 
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ingestion by macrophages and other cells the asbestos fibres become covered by iron 
deposit and iron-rich proteins49. These ferruginous bodies (figure 2c) may lead to 
increased formation of reactive oxygen species (ROS). ROS lead in their turn to cellular 
damage, especially DNA mutations55, and have been linked to tumour progression56. 
Macrophages that try to phagocytose the asbestos fibres fail, but in the process produce 
more ROS and cytokines57 (see section below concerning IL1β, TNFα and HMGB1). This 
so called frustrated phagocytosis is part of a chronic inflammation in the lung and 
pleura. The clastogenic properties of the asbestos fibres, the increased ROS production 
along with a never-ending inflammation are thought to be some of the main causes of 
malignant mesothelioma58 and a dose-dependent effect has been described59. For 
details on the molecular pathogenesis of malignant mesothelioma see section 1.2.3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
Simian Virus 40 
Simian virus 40 (SV40) is a DNA virus known to infect monkeys. It seems to have been 
introduced to the human population by contaminated polio-vaccines in the 1950s and 
1960s60, but can possibly transmit horizontally as well. The question of whether SV40 
has a causal role in malignant mesothelioma development has been discussed for many 
years. 
 Studies show that blue asbestos together with SV40 cause mesothelioma in a 
synergistic fashion in hamsters61. Molecular investigations imply that the large T-antigen 
of the virus is able to inhibit several tumour suppressor genes (including p5362 and 
pRB63). However, other studies warn for false positive detection of SV4060. For an 
overview on the SV40 controversy, please see references 64 and 65. 
 
Smoking 
Remarkably, there is no connection between smoking and malignant mesothelioma12,66 
as there is for a multitude of other human malignancies67. On the other hand, smoking 
and asbestos induce lung cancer in a synergistic manner68. 
 
1.2.3.3 Molecular pathology of malignant pleural mesothelioma 
Only 5 to 10 per cent of individuals that are heavily exposed to asbestos develop 
malignant mesothelioma11. This may indicate an underlying factor in these persons that 
make them susceptible to the fibre; perhaps a contribution of genetic predisposition 
 
Box 1: Asbestos the “miracle fibre” 
Asbestos was held in high regards 
during parts of the 20
th
 century. Its heat 
resistant capacity was even regarded 
potent enough to stop superheroes.  
   Or at least it was tried by two super-
villains: the Asbestos Lady and later the 
Asbestos Man. They both fell short. 
Only the Asbestos Lady reappeared, this 
time with a cancer diagnosis. Images 
are reprinted with permission from 
Marvel Comics©. 
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and complex relationship to environmental influences (e.g. duration of asbestos 
exposure or SV40 infection).  
As with all cancers, malignant mesothelioma is caused by a series of genetic changes 
and aberrations, a few are well known and well described. Increasing knowledge of 
these molecular changes might allow screening of risk groups for early detection and 
designing novel therapeutic alternatives. Studies in animals and humans have shown 
extensive chromosomal rearrangements and losses, particularly of chromosome 22, but 
also 1p, 3p, 6q and 9p22,43. Several of the affected loci contain important tumour 
suppressor genes, such as neurofibromin 2 (22q12), p16 and p14 (both located in the 
CDKN2A locus at 9p21) and BRCA1-associated protein 1 (3p21)69. 
 
Neurofibromin 2 
Heterozygous loss of neurofibromin 2 (NF2) has been reported in up to 100 per cent of 
mesothelioma cell lines70 and in approx. half of all mesothelioma patients. The product 
of the NF2 gene is merlin (moesin-ezrin-radixin-like protein), a membrane-cytoskeleton 
scaffolding protein, linking actin filaments to cell membrane or membrane 
proteoglycans71. Merlin asserts tumour suppressor properties through contact-
mediated growth inhibition via the hippo and mTOR pathways, and via transcriptional 
control of integrins and receptor tyrosine kinases72. At least 75 per cent of 
mesothelioma patients show inactivation of merlin, SAV1 or LATS2 (two proteins 
downstream in the hippo pathway)73. 
 
The CDKN2A locus 
The CDKN2A locus is an important genetic segment containing the tumour suppressor 
genes p16INK4A and p14ARF. These tumour suppressors are the product of exon splicing74. 
p16 prevents phosphorylation of pRB by binding CDK4/675, which in turn prevents the 
cell going  through the G1 and S phases. The alternative splice variant p14 is involved in 
MDM2 sequestering and/or degradation, facilitating both pRB and p53 stabilisation and 
thereby arresting cells in G1 and G2 cell cycle phases76,77. So even though p53 itself is 
rarely deleted or mutated in malignant mesothelioma,78 it is indirectly silenced through 
the loss of p14. Disruption of the CDKN2A genes are linked to the development of 
several cancers79 and the loss of p16 expression is considered an essential event in the 
development of malignant mesothelioma80,81.  
 
BRCA1-associated protein 1 
The BRCA1-associated protein 1 (BAP1) gene product is a deubiquitinase that 
translocates to the nucleus and interacts with the BRCA1 protein82. Current studies have 
reported an association with BAP1 deletion or mutation and malignant mesothelioma. 
In one study, the analysis of the genome revealed inactivating mutations in 12 of 53 
mesothelioma patients, while the well-known tumour suppressors PTEN and p53 had 
few or no mutations83. It has also been shown that individuals with germline mutations 
of BAP1 are predisposed to develop malignant mesothelioma84. The inactivation of BAP1 
in mesothelioma seems to be more specific for the epithelioid phenotype, with 81 per 
cent of these patients having mutations compared to 14 per cent of non-epithelioid 
cases85.  
 8 
Asbestos activated pathways 
As already touched upon, several pathways can be activated in normal and malignant 
mesothelial cells by the asbestos fibres themselves, their involvement in ROS generation 
or their incomplete phagocytosis86. The first study to show that asbestos fibres could 
interfere with the molecular machinery of cells, reported a dose-dependent induction of 
c-fos and c-jun mRNA as a response to blue asbestos in pleural mesothelial cells87. The 
two proteins c-fos and c-jun heterodimerize to form activator protein 1 (AP1) and in 
response to extracellular stimuli this transcription factor binds DNA and regulates the 
expression of several proteins involved in proliferation, differentiation and apoptosis88. 
It has also been shown that the asbestos fibre itself can directly interfere with and 
activate the epidermal growth factor receptor (EGFR) in mesothelial cells86. This 
receptor normally responds to various ligands (e.g. EGF, transforming growth factor α 
and heparin-binding EGF)89 and can be the oncogenic addiction of many cancers90.  
 Blue asbestos fibres can dimerize EGFRs leading to autophosphorylation and lead to 
induction of extracellular signal-regulated kinases (ERK) 1 and 2. ERK1/2 stabilization of 
c-fos is regulated by fra1 in mesothelial cells86. Fra1 is needed for AP1-dependent 
mesothelial cell growth, migration and transformation91. Further studies elaborate on a 
link between ERK1/2 and fra1 expression of c-met and CD44 (hyaluronan receptor)92, 
two proteins involved in cancer initiation and progression. Fra-1, c-met and CD44 may 
be partly responsible for mesothelioma invasion92,93. Asbestos fibres have also been 
shown to elicit a NFkB response in mesothelial cells in vitro. NFkB is a transcription 
factor linked to proliferation, apoptosis and chemokine/cytokine production86. 
 
IL1β is a chemokine produced by macrophages and can be induced as a response to 
asbestos mediated killing of mesothelial cells. When asbestos induced cell damage 
occurs in the mesothelium, HMGB1 (a DNA binding protein and a cytokine for 
inflammation contained in the nucleus) is released and in response macrophages 
secrete IL1β and TNFα – leading to inflammation in the tissue. The mesothelial cells can 
express receptors for both IL1β and TNFα (TNFR), initiating a paracrine loop for 
maintained survival and proliferation94; a survival that might partly be NFkB95 and 
IL1/AP1-dependent. Some studies also show TNFR activation through asbestos fibres 
and/or ROS86. This might lead to the survival of damaged mesothelial cells with 
increased transformation potential.  
 
Furthermore, malignant mesothelioma is frequently associated with certain growth 
factors and cytokines, including increased levels of secreted PDGF, HGF, FGF, VEGF; IL6, 
IL8 and TGFβ. Some can be produced by mesothelial cells due to inflammation; possibly 
acting in autocrine manner to aid survival, and/or affecting surrounding stroma to 
facilitate angiogenesis and invasion. Various forms of PDGF have long been known to 
have an effect on malignant mesothelioma cell proliferation14,58,96,97 and chemotaxis98. 
Human mesothelial and malignant mesothelioma cell lines secrete TGFβ99 and inhibition 
of TGFβ receptors reduce the proliferative potential of murine mesothelioma cells100,101. 
It is known that there is a cross-talk between TGFβ and the hippo pathway102 in 
mesothelioma cells103 linking the pivotal NF2 deletions with the plasticity of malignant 
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mesothelioma. For two comprehensive reviews on asbestos affected pathways in lung 
epithelia and pleural mesothelium, see references 86 and 94. 
 
1.2.3.4 Mesothelioma phenotypes and epithelial-mesenchymal transition 
Malignant mesothelioma originates in a mesenchymal tissue. The histology of the 
cancer is represented clinically by three different growth patterns: epithelioid, 
sarcomatoid and a mixture of these two, called biphasic. Estimates of the different 
forms vary, but the epithelioid is the most common finding (50 to over 70 per cent), 
usually followed by the biphasic (10 to 40 per cent), while the sarcomatoid only 
constitutes 10 to 15 per cent of all mesothelioma cases12,103,104. However, these 
fractions will be influenced by the diagnostic technique and size and number of 
examined biopsies – it might be that the biphasic phenotype is more prevalent if 
mesothelioma tumours were even more carefully examined105. The phenotypes are 
closely linked to patient survival, the median survival time has been reported to fall 
from 12 months for epithelioid mesotheliomas to only 4 months for sarcomatoid 
mesotheliomas106. 
 
The mesothelial cells of the pleura have the ability to transdifferentiate between an 
epithelioid and a fibroblast-like phenotype107,108. This observation is confirmed in 
embryological and cell culture experiments which demonstrate that mesothelial cells 
may display fibroblast-like characteristics under certain conditions14,109. 
 Some differences have been shown between the two phenotypes. In a qPCR based in 
vitro experiment it was reported that epithelioid mesothelioma cells produced more 
membrane bound proteoglycans (syndecan-2 and syndecan-4) as well as hyaluronan 
synthase, while sarcomatoid mesothelioma cells overexpressed extracellular 
proteoglycans (versican, decorin and biglycan). Furthermore, silencing of syndecan-1 by 
antisense targeting, morphed an epithelioid cell shapes into more a fibroblast-like.110 
Moreover, mesothelin is expressed in greater quantities from epithelioid 
mesotheliomas111 and to some extent so is hyaluronan112. 
 
When a cell changes from an epithelial to a fibroblast-like phenotype, this is called 
epithelial-mesenchymal-transition (EMT). EMT is a feature of invasive carcinomas and 
intertwined with the hallmark of cancer – invasion and metastasis – that presents one of 
the greatest challenges in cancer treatment today. The change in morphology enables a 
proliferative cancer in situ to start migrating and invade surrounding tissue, eventually 
leading to the seeding of daughter cells.113 EMT will lead to loss of cell-to-cell contacts 
and initiation of a migratory (invasive) programme. Some of the factors that seem to be 
responsible for this transformation include a loss of: E-cadherin, syndecan-1, MUC1 and 
cytokeratin to a gain of: N-cadherin, αSMA, β-catenin, vimentin, desmin and α5β1 
integrins.113-115 However, this transition should best be viewed as a tissue specific and 
graded continuum. The induction and aiding of EMT in carcinomas has been linked to 
signals emanating from the tumour-associated stroma (notably, HGF, EGF, PDGF, 
metalloproteases and TGFβ) and as an intrinsic drive from the tumour itself.113,116 
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 Interestingly, studies acknowledge the resemblance between malignant 
mesothelioma and EMT, arguing that the three mesothelioma phenotypes (epithelioid, 
sarcomatoid and biphasic) could be actual snap-shots of the EMT axis117,118. When 
analysing epithelioid to sarcomatoid mesothelioma tissues, a switch from epithelial to 
mesenchymal markers were seen in the direction of EMT (e.g. loss of E-cadherin with an 
increase in N-cadherin and vimentin). Moreover, inhibition of two mesenchymal 
markers (ZEB1 and ZEB2) led to increased E-cadherin expression and reduced migration 
and invasion of mesothelioma cells in vitro118. Another study evaluating the role of EMT 
in mesothelioma analysed 29 genes involved in EMT or stemness and found that they 
distinguished mesothelioma histology from normal pleura and lung tissue117.  
 However, other studies show that even though mesothelioma can express both E-
cadherin and N-cadherin, the mesothelial marker NCAM is predominant in both 
phenotypes119 and a large proportion of epithelioid mesotheliomas express vimentin120. 
It should furthermore, not be forgotten that it can be difficult to distinguish EMT from 
the reversal mesenchymal-epithelial-transition (MET) which is needed for secondary 
tumour formation at a new location121. Still, evidence for an EMT-like description of 
malignant mesothelioma is intriguing and might carry validity. 
 
1.2.4 Diagnosis 
Whenever a patient presents with dyspnoea due to a pleural effusion and chest wall 
pain the probability of a malignant mesothelioma must always be considered22. The 
diagnosis is difficult and often a lengthy process. The main differential diagnoses to a 
malignant mesothelioma are metastatic adenocarcinomas (most often from the breast, 
adjacent lung or ovary) and benign mesothelial hyperplasia122. 
 
The clinical procedure in short: imaging with chest x-ray can show the effusion and the 
tumour or pleural thickening. Computed tomography can show a pleural mass and 
invasion (figure 2d). More advanced imaging techniques, such as magnetic resonance 
imaging and positron emission tomography can be helpful in evaluating tumour 
likelihood, invasiveness and staging. Staging is of little importance for medical 
management, however it is useful in planning surgical management of malignant 
mesothelioma.22 
 
1.2.4.1 Morphological evaluation 
It has been recommended that the mesothelioma diagnosis should be based on 
histological assessment of biopsy material123. To obtain sufficient material for the 
diagnosis, the biopsy should preferably be taken during thoracoscopy or thoracotomy. 
Coarse-needle biopsies are used less today due to problems with the diagnostic yield 
and high complication rate.124 
A specific diagnosis can also be obtained based on effusions that often are sampled 
early in the process. Cytology together with ancillary analyses will provide an early 
diagnosis in a large proportion of cases.22,125-127 
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FIGURE 3. Transmission electron 
microscopy of a mesothelioma cell 
prepared from cytological material. The 
mesothelioma cell is surrounded by 
leukocytes and erythrocytes. Note the 
multitude of slender microvilli running 
the length of the mesothelioma cell 
(arrows). Kindly provided by Docent K. 
Hultenby. Bar is 5 micrometres. 
Histology and immunohistochemistry 
Haematoxylin-eosin staining of tissue sections for light-microscopy, together with 
immunohistochemistry will allow for classification of a large proportion of the patients. 
The recommendation for tissue markers are at least two positive and two negative 
markers with no less than 80 per cent sensitivity or specificity123. For example, calretinin 
will stain most cells of mesothelial origin, and NCAM, epithelial membrane antigen 
(EMA) with cell membrane accentuation and Wilms’ tumour 1 are indicative of a 
mesothelioma, while CD15, B72.3 and Ber-EP4 are often negative in malignant 
mesothelioma. Desmin and the glucose transporter 1 can be used to separate a 
malignancy from a benign reaction, so can necrotic areas in some instances – less useful 
are mitotic index and cytological atypia.104,123,128,129 
 
Cytology and immunocytochemistry 
Sixty to eighty per cent of pleural mesothelioma patients present with an effusion at 
their first clinical examination22,35, but as many as 95 per cent develop an effusion 
during the course of the disease35. Thoracentesis is required for these patients to relieve 
the discomfort of effusion. With minimal invasion, effusions and exfoliated cells will 
hence be available for analysis and it has been estimated that 92 per cent of 
thoracocenteses can provide clinically useful information130. A pleural effusion is 
however, a sign that the disease has already progressed and most mesotheliomas are 
diagnosed at stage IV21. 
 
 Cells extracted from various bodily fluids are examined in the diagnostic routine for 
several human diseases. However, cytology has had historical difficulties to establish 
itself as a diagnostic alternative for malignant mesothelioma123,131. Still, when a serous 
cavity is affected by disease, an exudate with exfoliated cells is often the first symptom. 
By incrementing the procedure with specific antibodies (similar to those for immuno-
histochemistry) and ancillary measures such as fluorescence in situ hybridization132, 
electron microscopy (EM; figure 3)133 and 
chemical analyses of biomarkers in the effusion 
supernatant, cytology should be recognised as a 
minimal-invasive and quick arm of mesothelioma 
diagnosis22,125-127. 
 
1.2.4.2 Soluble biomarkers 
The measurement of disease specific markers in 
patient material has a long history in the clinical 
routine and taking the step to an personalized 
patient care in the future will greatly rely on 
accurate biomarker evaluation134. 
The quantification of soluble markers in pleural 
effusions, serum and plasma can be invaluable 
complements to morphological examination of 
malignant mesothelioma. These measurements 
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could speed up diagnosis, increase accuracy, predict treatment outcomes, survival and 
be used to follow treatment efficacy. Additionally, blood based tests could be used to 
monitor risk groups for mesothelioma (i.e. individuals with known asbestos exposure 
and/or known gene alterations) and detect signs of early disease. However, today there 
are few options of soluble biomarkers with high enough accuracy for a malignant 
mesothelioma135,136. 
 
Mesothelin 
In humans, the MSLN gene coding for mesothelin is found on the 16p13.3 locus. Its 
glycosylated product is one of the most evaluated soluble mesothelioma biomarkers 
today. Mesothelin was first described by Chang et al. in 1992 as being expressed by 
ovarian carcinomas and mesothelial tissues137; the name even refers to its strong 
mesothelial expression. Mesothelin has been characterised as a membrane-bound 
protein anchored by a glycosyl-phosphatidylinositol (GPI) link, which is evident by its 
release after phosphatidylinositol phospholipase C treatment138. Mesothelin has 4 
isoforms: mesothelin 1 to mesothelin 4. Isoform 1 is considered the canonical sequence, 
isoform 2 has a 24 base pair insertion and isoform 3 has a 82 base pair C-terminal 
insertion, while isoform 4 differs only by lacking a glutamic acid at position 44139. 
Isoform 3’s C-terminal insertion predicts a soluble form and was assumed to be the 
main isoform detected in fluids from mesothelioma patients. However, additional 
research has shown that this is rarely the case; the primary found isoform is mesothelin 
1. This protein is occasionally named as pre-pro-megakaryocyte potentiating factor. 
Post-translational cleavage by trypsin-like, or furin-like proteases, creates a C-terminally 
peptide (~40kDa) as well as an N-terminal soluble peptide (~30kDa)140 (figure 4, upper 
part). The GPI-bound C-terminal protein is informally referred to as mesothelin or C-
ERC/mesothelin while the solubilized N-terminal 30kDa part is referred to as 
megakaryocyte potentiating factor or N-ERC/mesothelin. ERC is derived from studies on 
the Erc (Expressed in renal carcinoma) gene, which is a functional orthologue to 
mesothelin in the Eker rat model of hereditary renal carcinoma141. C-ERC/mesothelin 
has been shown to bind cancer antigen 125 (CA125 or MUC16). This interaction affects 
cell adhesion and migration and could be involved in the seeding of ovarian carcinoma 
cells in the abdominal cavity142. N-ERC/mesothelin is involved in the fate of 
megakaryocytes142,143. Otherwise mesothelin’s physiological roles are largely unknown. 
 
The diagnostic utility of C-ERC/mesothelin was first evaluated in sera from patients with 
ovarian carcinoma, where it was significantly upregulated compared to a control 
group144. The enzyme linked immune-sorbent assay (ELISA) established in this study was 
based on the monoclonal OV569 and 4H3 antibodies and was soon used to evaluate 
mesothelioma patients. The first study reported an encouraging 84 per cent sensitivity 
at 98 per cent specificity in serum111. Several studies have followed with similar 
results145-149. The OV569 and 4H3 based assay has since been marketed under the name 
MesoMark™ as a blood based test to aid mesothelioma diagnosis. This particular ELISA-
kit is the most readily used for this purpose in clinics as well as research today. 
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MesoMark™ has also been evaluated on pleural effusions from malignant mesothelioma 
patients147,148,150-155 where it also adds diagnostic information. 
 
The proteolytically generated N-ERC/mesothelin fragment of mesothelin was 
investigated later as a mesothelioma marker. N-ERC/mesothelin was first  found in a 
pancreatic cell line143 but further assessment showed a significant increase in sera from 
mesothelioma patients156,157; though, with less discriminatory capacity than C-
ERC/mesothelin158. Shortly after, a new N-ERC/mesothelin ELISA was constructed 
changing the detection antibody from a polyclonal to a monoclonal, thereby increasing 
accuracy159. This new ELISA has a diagnostic performance comparable with the 
MesoMark™-kit in sera from mesothelioma patients and controls160. 
 
Levels of C-ERC/mesothelin and N-ERC/mesothelin reflect tumour burden after 
administration of chemostatic drugs or surgical resection: both serum markers decrease 
initially and then increase almost to baseline levels before the recurring tumour is 
clinically measurable again. This indicates that both mesothelin fragments can be 
analysed longitudinally as surrogate endpoints. However, neither C-ERC/mesothelin nor 
N-ERC/mesothelin seem to be prognostic.161 
 Elevated levels of mesothelin in a patient with suspected mesothelioma clearly 
warrant further clinical investigation162,163. However, low sensitivity diminishes the 
possibility of using this biomarker as a screening marker in risk populations163. 
 
There are a few important pitfalls to keep in mind when measuring mesothelin related 
proteins in fluids: i) decreased kidney function might lead to increased serum levels of 
mesothelin164-166, ii) mesothelin levels increase with age159, iii) in addition to 
mesothelioma, mesothelin is produced and secreted by both ovarian and pancreatic 
carcinomas144,167 and iv) mesothelin is only produced by epithelial mesothelioma 
cells111,159. Taking into account these confounding factors, glomerular filtration rate 
should be monitored whenever assessing soluble mesothelin proteins and low levels of 
mesothelin never exclude a sarcomatoid mesothelioma. 
 Regarding kidney status, a recent study described a higher diagnostic performance of 
pleural C-ERC/mesothelin over serum C-ERC/mesothelin155. The explanation was that 
serum is more susceptible to changes in kidney clearance, as compared to pleural 
effusions. Furthermore, cytostatic treatment with platinum based drugs is known to 
cause nephrotoxicity168 and can thereby raise mesothelin values even in the absence of 
mesothelioma recurrence. 
 
Hyaluronan 
Hyaluronan is a linear glycosaminoglycan (GAG), formally known as hyaluronic acid or 
hyaluronate. Its structure consists of disaccharide repeats of glucuronic acid (GlcUA) and 
N-acetylglucosamine (GlcNAc) connected by β-linkages (GlcAβ(1→3)GlcNAcβ(1→4))169. 
The biosynthesis of hyaluronan is performed by hyaluronan synthase (HAS). In humans 
there exist at least three homologues: HAS1, HAS2 and HAS3. The HAS enzyme is 
imbedded in the plasma membrane of the cells and synthesise the growing hyaluronan 
chain out into the extracellular space (figure 4, middle).170 One molecule of hyaluronan 
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can exceed 30,000 disaccharide repeats; amounting to several millions of Daltons (Da) in 
molecular weight171. The architecture is simple but also very peculiar in character since 
it is the only known GAG that is not linked to a protein, or sulphated172. Degradation 
occurs by hyaluronidases and is rapid: hyaluronan is degraded when passing the liver 
and its half-life in blood is only a few minutes173. 
 
Hyaluronan was described for the first time in isolates from the vitreous humour 
(hyaloid in Greek) of a cow’s eye174, but seems to be omnipresent in vertebra tissue171. 
Hyaluronan is involved in several physiological processes and can for example activate 
CD44 (hyaluronan receptor) in various cell types. This interaction leads to induction of 
VEGF synthesis and cellular proliferation in endothelial cells175. Recent evidence 
indicates that hyaluronan-CD44 interactions help to regulate fibrocyte differentiation 
following tissue injury176. The CD44 receptor is known to participate in cell adhesion, 
proliferation, cellular growth and survival, motility, invasion and differentiation177-179. 
 Hyaluronan is involved in angiogenesis180 inflammation and cytokine induction181, 
and rapid cell proliferation182,183. Conditioned media from mesothelioma cells induce 
hyaluronan expression in fibroblasts184 and hyaluronan is also known to be expressed in 
tumour stroma of breast, ovarian and prostate cancers, which correlates with a poor 
prognosis for the patient185. Hyaluronan asserts a multitude of specific cellular functions 
dependent on its molecular weight, temporospatial expression and interactions with 
hyaladherins (hyaluronan binding proteins). 
 
Six years after its discovery, hyaluronan was shown to be increased in effusions from 
mesothelioma patients186. Hyaluronan can be demonstrated using high pressure liquid 
chromatography (HPLC)187, high performance capillary electrophoresis (HPCE)188 or 
electrophoresis189 as well as ELISA based techniques. Hyaluronan detecting ELISA 
methods utilize various hyaladherins as capturing entities190. Elevated concentrations of 
hyaluronan in mesothelioma effusions have since been demonstrated by several 
authors153,186,191-199. This linear GAG is a soluble mesothelioma biomarker with high 
specificity, but limited sensitivity for a malignant mesothelioma. At 100 per cent 
specificity the sensitivity ranges from circa 50 to 60 per cent153,196,197. Hyaluronan 
expression seems to be indicative for the epithelioid phenotype198,199. Additionally, 
hyaluronan might carry prognostic information200. 
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FIGURE 4. Established biomarkers for mesothelioma diagnosis and the syndecan family.  
Upper part: Mesothelin is linked to the cell membrane with a glycosyl-phosphatidylinositol (GPI) link. 
Proteolytic cleavage generates a membrane bound (C-ERC/mesothelin) and a solubilised (N-
ERC/mesothelin) fragment. Middle: Hyaluronan synthase (HAS) is a family of enzymes responsible for 
hyaluronan synthesis. This glycosaminoglycan is made up of repeating glucuronic acid (GlcA) and N-
acetylglucosamine (GlcNAc) disaccharides. UDP = uridine diphosphate. Lower part: The syndecan 
family has four members. Their extracellular ectodomain (grey) differ between members. The 
transmembrane domain (dark grey) and the two conserved regions in the cytoplasm (black) show 
high sequence homology between members. The cytoplasmic variable region (white) exerts different 
functions for the syndecans. Black triangles indicate heparin sulphate attachment sites. Grey 
triangles indicate attachment sites for chondroitin sulphate. 
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There are some caveats that might affect hyaluronan sensitivity and specificity: i) due to 
the rapid turnover of hyaluronan in blood this marker is best suited for detection in 
other body fluids, such as pleural effusions. ii) Since degradation takes place in the liver, 
severe liver disease might lead to increased hyaluronan levels in serum201 and result in 
false positives. iii) Moderate levels of hyaluronan are also measured in empyema, 
bacterial infections (where the bacteria synthesize hyaluronan202), metastatic disease203 
and in serum of patients with rheumatoid arthritis204. 
 
Osteopontin 
Osteopontin is a heavily post-translationally modified matricellular protein produced by 
a smorgasbord of cell types. Osteopontin isoforms range in size from 41 to 75 kDa and 
are expressed as secreted glycophosphoproteins with several functional domains. 
Osteopontin has been linked to many cellular functions including immune modulation, 
wound healing, angiogenesis, bone remodelling, tumour progression and metastasis. 
Osteopontin also works as a chemoattractant for macrophages and monocytes. 
Furthermore, osteopontin promotes cell survival, chemotaxis and adhesion through 
interactions with CD44 and various integrins and also potentiates invasion (for a review 
see reference 205). The CD44 interaction, and metastasis formation, can be out-
competed by hyaluronan206. Osteopontin is expressed in several human cancers, 
including melanoma207, lung208, head and neck209, colorectal210, cervical211, breast212, 
ovarian213, gastric214 and prostate215 carcinomas. 
 
A transcriptomic profiling linked osteopontin to mesothelioma216 and a validation study 
showed strong reactivity for the protein in tissue sections as well as increased levels in 
serum from mesothelioma patients217. This first study reported a promising diagnostic 
ability of osteopontin. However, validation studies from other groups never reached the 
same diagnostic performance, either in sera, plasma or pleural effusions147,158,218-221 and 
osteopontin’s role as a diagnostic mesothelioma biomarkers seems to be limited. 
 Higher levels of osteopontin in pleural effusions seem to predict shorter patient 
survival. Osteopontin levels also appear to mirror the effect of chemotherapy as well as 
the response to surgical resection of the tumour. However, there are conflicting data 
and the changes are not as clear as for C-ERC/mesothelin and N-ERC/mesothelin.222 
 
To be aware of when measuring osteopontin for diagnostic purpose: i) the general 
problem with osteopontin is low specificity in most settings, which is due to 
osteopontin’s involvement in a multitude of cancers and other conditions. ii) The 
osteopontin protein has several internal cleavage sites for proteolytic degradation by 
thrombin and matrix metalloproteases223,224. This means that the protein is easily 
degraded and lost for immunogenic analyses that target the native form. It is preferable 
to measure osteopontin in plasma since it seem more stable220,221. iii) As with 
mesothelin, osteopontin is also negatively correlated to the glomerular filtration rate166. 
iv) Additionally, the different isoforms of osteopontin seem to have different properties 
in malignant mesothelioma225 and different splice variants of the protein might be more 
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accurate than others for diagnostic measures. v) Lastly, the analysis of osteopontin is 
strictly dependent on which ELSIA-kit is used226, perhaps reflecting isoform diversity.  
 
Novel diagnostic biomarkers and biomarker panels 
In a set of meta-analyses the usage of minimal-invasive laboratory tests to assess 
biomarkers were deemed of limited help when diagnosing a malignant 
mesothelioma135,136,162,163. Hence, novel biomarkers, or a combination of biomarkers to 
improve the diagnostic accuracy of this disease are needed. 
 It is improbable that a single biomarker would uphold both excellent sensitivity and 
specificity. The idea of combining biomarkers is to utilize their incremental value. For 
example one biomarker may correctly classify the mesothelioma patients (high 
sensitivity), while another correctly excludes all non-mesothelioma patients (high 
specificity). On the other hand, two biomarkers might both classify mesothelioma 
patients, but different ones, and together have high sensitivity. A different approach to 
aid the diagnosis of mesotheliomas by soluble compounds is the search for specific anti-
tumour immune responses227. 
 
Thioredoxin 
Thioredoxin-1 is a 12kDa redox enzyme involved in the cellular defence against oxidative 
stress. It has been shown to increase proliferation228 and inhibit apoptosis229. 
Upregulation of thioredoxin has been reported in some cancers229 and DNA binding of 
NF-kB and AP-1 may be thioredoxin-1-dependent230. Mesothelioma cells often have 
upregulated levels of both thioredoxin-1 and thioredoxin reductase231,232.  
 The clinical role of thioredoxin-1 has been evaluated recently, in serum from both 
malignant pleural233 and peritoneal234 mesothelioma patients. Thioredoxin-1 could 
distinguish pleural mesothelioma patients from benign and lung cancer patients and 
possibly had prognostic value233. Thioredoxin also seemed to aid the diagnosis of 
peritoneal mesothelioma patients compared to asbestos exposed control patients234. 
These studies were rather small and need validation with more representative control 
groups. Still, thioredoxin seems to play a role in malignant mesothelioma pathogenesis 
and possibly in its diagnosis. 
 
Apolipoprotein-CI 
Apolipoprotein-CI achieved similar accuracy as C-ERC/mesothelin when using MALDI-
ToF to screen pleural effusions from mesothelioma patients235. When comparing 41 
mesotheliomas to 48 effusions from other cancers and benign disease, apolipoprotein-
CI outperformed osteopontin, CYFRA21-1 and human epididymis protein 4235, which has 
earlier been described as upregulated in mesotheliomas compared to benign 
conditions236. Hence, apolipoprotein-CI is a candidate that warrants further 
investigation. 
 
Fibulin-3 
A recent study verified and validated fibulin-3 as a potent new soluble biomarker for 
malignant mesothelioma237. The study was based on a former gene expression analysis 
where fibulin-3 was described as being upregulated in diffuse malignant peritoneal 
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mesothelioma238. Fibulin-3 is a member of the extracellular glycoprotein fibulin family. 
Its expression is sparse in normal adult tissues where fibulin-3 is involved in cell-to-cell 
and cell-to matrix communication, supressing proliferation and having angiogenic 
effects. Suppression of fibulin-3 has been reported in several cancers.237 However, the 
protein is also upregulated in metastatic adenocarcinoma of the pancreas239. 
 Fibulin-3 levels were measured in plasma, pleural effusions as well as serum from 
pleural mesothelioma patients and controls (including other cancers and asbestos 
exposed individuals)237. Initial findings showed an excellent diagnostic accuracy. 
However, in one blinded validation it failed to diagnose malignant mesothelioma. It was 
speculated that this could be due to proteolytic degradation since there are at least two 
reported thrombin cleavage sites in the protein240. In a second blinded validation study 
it showed significant diagnostic value. Furthermore, pleural effusion levels of fibulin-3 
increased with the stage of the disease, and were associated with shorter survival. After 
cytoreductive surgery fibulin-3 plasma levels dropped significantly, possibly enabling its 
use as a surrogate endpoint. The staining intensity and distribution of fibulin-3 were 
similar in epithelioid, biphasic and sarcomatoid mesothelioma as evident by 
immunohistochemistry. This was however, not evident for fluid levels. Fibulin-3 is a 
highly interesting novel biomarker for malignant mesothelioma. It needs to be 
compared to mesothelin and hyaluronan levels and corrected for kidney function before 
it can be used in clinical diagnosis, possibly in a panel of biomarkers. 
 
Combination of established markers 
Combinations of the most established markers seem to be difficult. An effort to join 
hyaluronan and C-ERC/mesothelin was considered of no clinical use153. The same was 
concluded when trying to combine osteopontin and C-ERC/mesothelin220, C-
ERC/mesothelin and N-ERC/mesothelin160, or all three of them (C-ERC/mesothelin, N-
ERC/mesothelin and osteopontin)158. In paper I, however, such a model is possible to 
establish. 
 
Combining C-C motif chemokine 2, galectin-3, and C-ERC/mesothelin 
Based on a previous genome-wide gene expression analysis C-C motif chemokine 2, 
galectin-3, and C-ERC/mesothelin combination improves the diagnosis of mesothelioma 
in pleural effusions241. In this study the markers were combined in a logistic regression 
model and assessed on pleural effusions. The model increased the diagnostic accuracy 
of a malignant mesothelioma over C-ERC/mesothelin alone. However, this panel needs a 
proper external validation. 
 
Genome and proteome screenings  
Omics screenings have combined large arrays of markers to enhance diagnostic 
accuracy for malignant mesothelioma216,238,242. The omics approach is probably the 
ultimate combinatorial effort. However, results including tens or hundreds, even 
thousands, of variables are hard to evaluate and there is often a considerable decrease 
in the diagnostic performance at validation (if validated at all). At present it might 
furthermore be technically difficult to implement such a measure in the routine clinic; a 
situation that will hopefully change in the future. Omics studies are on the other hand 
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excellent ways of discovering novel biomarkers associated with a certain 
disease.235,237,238,243 
 A new technique used slow off-rate modified aptamers (SOMAmers™), which are 
oligonucleotides with affinity for proteins (or any molecule). In a sequential manner 
these SOMAmers can quantify thousands of proteins with reportedly high sensitivity 
and specificity243. This rather novel multiplexing technique was used to evaluate serum 
from 117 malignant pleural mesothelioma patients and 142 asbestos-exposed controls. 
Measuring approx. a thousand proteins, a model composed of 13 proteins showed 
excellent diagnostic capability in training, as well as in an independent blinded 
verification and validation. The model however lacks sensitivity for the diagnosis of 
malignant mesothelioma at high specificity.244 
 
1.2.5 Proteoglycans  
1.2.5.1 Structure 
Proteoglycans are expressed on all nucleated cells in humans and regulate many cellular 
processes245. As the name suggests proteoglycans are proteins with covalently attached 
glycosaminoglycan (GAG) chains at specific locations. These GAG chains are linear 
polysaccharides with negative charge. They are repeats of disaccharides composed of a 
hexuronic acid and a hexosamine making up four classes of GAGs: heparan sulphate 
(HS), chondroitin and dermatan sulphate (CS and DS, respectively), keratan sulphate and 
hyaluronan. HS, CS and DS are the three major GAGs found on proteoglycans, while 
hyaluronan is the only GAG not connected to a core protein246,247. The syntheses of 
GAGs are non-template driven and lack proof-reading. All GAGs except hyaluronan are 
synthesised and attached to their core protein in the Golgi apparatus by a set of 
enzymes in a specific sequential order (sometimes referred to as the GAGosome). These 
enzymes are expressed in isoform and tissue specific patterns248 and the final GAG 
chains can make up the majority of the proteoglycans final weight249. The core protein, 
number and length of GAGs as well as GAG modifications (e.g. sulphation) will to a great 
extent determine the biological function of each proteoglycan247. 
 
1.2.5.2 Location of proteoglycans 
Depending on their cellular localisation the proteoglycans are classified further into 
three groups: tethered to the plasma membrane, secreted out into the ECM or retained 
in the cytoplasm. 
 The two main families of membrane bound proteoglycans, with four and six 
members respectively, are syndecans and glypicans, but CD44 and a few others have 
been characterised247,250. The syndecans are intercalated in the membrane via a 
hydrophobic transmembrane segment in their core proteins, while the glypicans are 
attached with a GPI-anchor. These proteoglycans are considered to be co-receptors for 
heparin-binding mitogenic growth factors. 
 The extracellular proteoglycans include large aggregating proteoglycans called 
hyalectans and small leucine-rich proteoglycans (SLRPs). Versican belongs to the 
hyalectans while decorin and biglycan are both members of the SLRP family. Hyalectans 
 20 
have the ability to bind hyaluronan through their N-terminal globular domain. Biglycan 
is thought to be the result of decorin gene duplication.  
 Serglycin is the only known intracellular proteoglycan and is found in haematopoietic 
and endothelial cells. Serglycin interacts with histamine and TNFα and is important for 
the storage of these inflammatory mediators in secretory vesicles.247 
 
1.2.5.3 Functions of proteoglycans 
Tethered to the membrane or secreted into the ECM, proteoglycans are involved in a 
myriad of cellular activities including cell-to-cell communication, adhesion, cell survival 
and differentiation. On a tissue level, proteoglycans are involved in angiogenesis, 
axonal-growth, tissue architecture and integrity. However, proteoglycans are seldom 
the primary receptors for various growth factors and cytokines, but rather act as co-
receptors to each ligands prototypic receptor.250 
 Versican, which is shown to be expressed by sarcomatoid mesothelioma cells110, has 
been shown to bind hyaluronan, CD44, EGFR as well as integrins and toll-like receptors. 
These interactions are HS and DS-dependent while others are mediated through the 
core protein. These interactions regulate cell adhesion, proliferation, apoptosis, 
migration, invasion and ECM assembly and are highly involved in cancer motility and 
progression. Furthermore, TGFβ has been shown to regulate versican expression in 
several sarcomas247. Decorin, also expressed by sarcomatoid mesothelioma cells110, is 
substituted with both CS and DS and has been described as an inhibitor of tumour 
growth251. It is understood that decorin inhibits tumour growth by preventing EGFR 
phosphorylation252. However, the opposite has also been shown247, underlining the 
importance of tissue and co-factor context for proteoglycan functions. 
 
1.2.5.4 Syndecans 
Expression 
As one of the major families of membrane bound proteoglycans, the four syndecans 
(syndecan-1 to syndecan-4) are expressed on the majority of human cells. They are 
evolutionary related and have orthologues in most species253. In humans, syndecan-1, 
often referred to as CD138, is expressed on epithelial cells and is a marker for plasma 
cells, syndecan-2 is synthesised by mesothelium, while syndecan-3 is common in 
neuronal tissue and syndecan-4 is expressed on most tissue254,255. For extensive reviews 
see the following references: 247, 256 and 257.  
 Syndecan-1 expression has been shown to be negatively regulated by TNFα, but only in 
the endothelium, while TGFβ induced syndecan-1 surface expression occurs on epithelial 
cells in a post-translational fashion257. Moreover, PDGF and TGFβ induce syndecan-1 
expression in human fibroblasts and osteoblasts258. These findings indicate tissue specific 
regulation. 
 The changes in syndecan levels can be controlled post-transcriptionally. This is evident 
for syndecan-1 protein levels that can increase drastically without changes in syndecan-1 
mRNA level. The cell surface increase of syndecan-1 could be dependent on cyclic AMP, at 
least in macrophages259 and syndecan-1 can be stored in cytoplasmic vesicles260. 
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 In contrast, high amount of syndecan-3 mRNA can be found in heart tissue where the 
protein is barely detectable. In addition, syndecan-1 expression is decreased in several 
tumours following malignant transformation, even though the mRNA levels stay 
unchanged259. The underlying mechanisms are often unknown. Furthermore, the 
syndecan family members seem to be able to regulate each other’s expression, possibly in 
a compensatory fashion261. 
 
Syndecan structure  
The syndecans are membrane proteoglycans with covalently bound HS. Additionally,  
syndecan-1 and syndecan-3 are substituted with CS256. HS and CS chains are attached to 
a serin residue in a serin-glycin motif, and starts with a xylose-galactose-galactose-
glucuronic acid tetrasaccharide, elongated with unbranched saccharides into a mature 
GAG chain249. The core proteins vary in length from 198 to 442 amino acids and in the 
number of attachment sites for GAGs. Syndecan-1 and syndecan-3 show the highest 
sequence homology within the family262, while syndecan-1 and syndecan-4 exhibit 
functional similarity263. Each individual syndecan core protein has long stretches of 
individual sequence, but also shares motifs. For a schematic representation of the four 
syndecans see figure 4, lower part; for a more detailed depiction of syndecan-1 see 
figure 5. 
 
The extracellular ectodomains vary between the four syndecans, but close to the 
membrane they share common cleavage sites for various proteases. The HS chains are 
attached close to the N-terminus on the ectodomain on all syndecans, while the CS chains 
have attachment sites close to the plasma membrane of syndecan-1 and syndecan-3. 
However, it has recently been postulated that CS can replace HS at some N-terminal sites 
in certain settings264. Below the HS chains are amino acid sequences thought to be 
involved in protein-protein interaction for syndecan-1 and syndecan-4265. 
 
The transmembrane domain of hydrophobic amino acids traverses the membrane once 
and anchors the syndecans. Also, the transmembrane domain contains a GXXXG motif 
important for syndecan dimerization. The syndecans dimerize to create homodimers and 
heterodimers that are essential for a majority of functions.266 
 
There is a short cytoplasmic C-terminal sequence which is composed of three motifs. 
Nearest the plasma membrane is a conserved region (C1), followed by a varied region (V) 
and ends with another conserved region (C2). The conserved regions are shared between 
syndecans, while the variable sequence is not. The C1 domain is thought to facilitate 
linkage to cytoskeletal filaments. This conserved domain starts with the consensus 
sequence: RMKKK, which has been proposed to be a novel nuclear localisation sequence 
for syndecan-1267. The intersectional V domain regulates cell spreading through actin and 
fascin bundling268, and in syndecan-4 the V domain has been shown to mediate binding 
and regulation of PKCα and PIP2. The C2 domain is also highly conserved and comprises 
an EFYA motif, responsible for binding PDZ-containing intracellular proteins such as ezrin 
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and syntenin. EFYA mediated bindings facilitates syndecan recycling, clustering, 
connection to the cytoskeleton and regulates several cellular functions250,256,269,270. 
 
Ligand affinity 
The syndecans bind various ligands in the ECM and can by doing so increase the 
concentration of growth factors and cytokines proximal to the plasma membrane, and 
also present ligands to their primary receptor250. Ligands the syndecans bind include: ECM 
components (e.g. fibronectin and laminins), growth factors (e.g. FGF2, VEGF and TGFβ) 
and several integrins. Binding is frequently mediated via the GAG chains or sometimes 
through specific parts of the core protein256. GAG binding is described as being mostly low 
in specificity, increasing the number of possible ligands271. Nonetheless, antithrombin has 
been shown to bind a highly specific HS sequence, emphasizing the importance of 
details272. The significance of intact GAG chains has been shown by the decreased effect of 
growth factors and ECM ligands after adding soluble competitors or disrupting GAG 
synthesis250. 
 FGF-2, which is a heparin binding factor with strong mitogenic activity has been shown 
to have association with all syndecans267,273,274. For example, it has been shown that 
syndecan-4 mediate FGF-2 signalling dependent on both HS and its cytoplasmic 
domain275. 
 
Cellular compartmentalization  
“Location, location, location!” 
– K. Dobra 
Traditionally syndecan-1 is thought of as an exclusively membrane bound proteoglycan. 
However, there is increasing evidence showing a more complex cellular distribution with 
major effects on function. Translocation to the nucleus of syndecan-1276 together with 
FGF-2 might regulate proliferation267 in a heparanase-dependent manner277. Nuclear 
localization has also been shown for other HS proteoglycans278. Syndecan-1 is also 
associated with tubulin276 and stored in intracellular vesicles260. Specific localisation of 
syndecans might be key for regulation and function. 
 
Shedding of the syndecan ectodomain 
Shedding of the syndecan ectodomain is a process with great impact on syndecan 
function. All syndecans have protease cleavage sites in their ectodomains close to the 
plasma membrane and the ectodomain is readily cleaved off and retrievable in cell 
culture media255 and body fluids.256 
 The shed ectodomain can bind the same ligands as when tethered to the cell surface. 
This means that solubilized syndecan ectodomain can sequester growth factors and 
cytokines, competing with cell bound receptors. In this fashion, soluble syndecan can 
assert opposite function to when cell-bound. Shed ectodomain can also bind and 
facilitate gradients of growth factors and chemokines/cytokines that cells can then 
migrate along247. The proteases facilitating ectodomain shedding of syndecan-1 are not 
all known, but several metalloproteases have been described279,280. Shedding can be 
accelerated by growth factors, chemokines, cellular stress281 and heparanase282. 
Furthermore, Rab5 regulates shedding via syndecan-1’s cytosolic domain283. 
   23 
Physiological and pathophysiological roles 
The syndecans affinity for such a plethora of ligands is mirrored by the vast quantity of 
cellular functions they affect. There is a well-established link to wound healing in vitro and 
in vivo250,256,257. The syndecans, furthermore, seem to play various roles in neuronal 
development, axonal growth and possibly regulating food consumption and weight 
gain256. 
 
The syndecans are involved in both adhesion and migration; two linked processes. The 
migratory cell response needs an optimal, intermediate adhesion phenotype, where the 
cell is not too loose, or too adherent284. Moreover, the initiated migration can be either 
random or directionally persistent. The latter can be caused by several external or intrinsic 
stimuli, as is referred to as chemotaxis285. Both syndecan-1 and syndecan-4 are involved 
in fibroblast adhesion and migration250,286. Syndecan-1 and αvβ3 integrins mediated cell 
spreading of a breast cancer cell line287. Overexpression of syndecan-1 leads to increased 
invasion of fibrosarcoma cells288 while syndecan-1 depletion increased adhesion, 
migration, and resistance to irradiation of breast cancer cells289. 
 
The syndecans are also involved in aspects of vascular physiology. Syndecan-1, syndecan-2 
and syndecan-4 have been implicated in vascular development and organization. Their 
angiogenic effect might in part be explained by syndecan specific HS interactions with 
thrombospondin-1 and thrombospondin-2. These two matricellular glycoproteins are 
well-known to inhibit angiogenesis in normal and malignant conditions, but also possess 
proangiogenic activity. Furthermore, syndecan-1’s V region seems important for 
thrombospondin-1 mediated adhesion of endothelial cells.256,257 
 Syndecan-1 furthermore regulates angiogenesis through core protein interaction and 
activation of αvβ3 and αvβ5 integrins in human mammary carcinoma cells. The peptide 
synstatin (amino acid 82 to 130 in the ectodomain of syndecan-1; figure 5) was found 
responsible and identified to have strong antiangiogenic properties in a mouse model290. 
It has since been shown that synstatin selectively inhibits a syndecan-1 coupled IGF1R-
αvβ3 integrin complex in angiogenesis and tumourigenesis, and its role as a novel 
therapeutic strategy is discussed291. 
 
The syndecans partake in many different pathological conditions, including cancer, viral 
infections (HIV can in some cases be syndecan-1-dependent), obesity and myocardial 
infarctions (as reviewed in reference 256). 
 The syndecans have been implicated in the regulation of many aspects of cancerous 
growths. Syndecan-1 has been connected to diagnosis, patient survival, differentiation 
and tumour stage; proliferation, invasion and angiogenesis of many carcinomas.290,292-295 
Overall, the published research points to a strong link between syndecan-1 and cancer. 
Again it should be noted that the effects asserted by syndecan-1 seem to be cell type 
and context dependent. 
 
The importance of cellular distribution, including ectodomain shedding, was illustrated 
in a study where mammary adenocarcinoma cells were transfected with different 
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constructs of syndecan-1. One construct expressed a membrane bound syndecan-1 and 
one translated to a constitutively shed syndecan-1. In this model, membrane bound 
syndecan-1 was associated with proliferation, but decreased invasiveness, while cells 
constitutively shedding syndecan-1 proliferated less but were more invasive296. In 
another study, a shed polypeptide of syndecan-1 promoted invasion in an epithelial cell 
line297.  
 These findings stand in stark contrast to the effects of shed syndecan-1 in myeloma 
cells in vivo where transfection of the syndecan-1 ectodomain increased myeloma cells 
proliferation298. These seemingly conflicting results are probably due to cell type specific 
effect of syndecan-1. There are additionally studies on GAG chain and their 
modifications relating to disease states. In malignant myeloma it has been shown that 
syndecan-1 HS has a greater amount of sulphated motifs than benign plasma cells299. 
This could increase HS affinity for mitogens and angiogenic factors and thereby promote 
cancer progression. 
 
Since syndecan-1 is predominantly expressed on epithelial cells300 and syndecan-2 is 
abundant in mesenchymal tissue301, they have been proposed as a tool for 
distinguishing between adenocarcinomas and malignant mesothelioma302,303. In 
mesothelioma, syndecan-1 correlates to cell differentiation304 and overexpression of 
syndecan-1 has been correlated to induction of epithelial morphology and inhibition of 
proliferation261. Additionally, loss of syndecan-1 in epithelial cells leads to an epithelial 
to mesenchymal transformation305. However, only a handful of studies have addressed 
syndecan-1’s role in malignant mesothelioma. 
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FIGURE 5. Schematic view of syndecan-1 and its glycosaminoglycans (GAG). The core protein is 
comprised of an extracellular ectodomain (ED), a transmembrane domain (TM) and a cytoplasmic 
domain (C1, V and C2). Heparan sulphate (HS) and chondroitin sulphate (CS) attach to serine 
residues in a serine-glycine motif (-SG-).
3
 HS and CS start with a tetrasaccharide of xylose-
galactose-galactose (-xyl-gal-gal-) and a glucuronic acid (GlcA). HS is synthesised by alternate 
adding of N-acetylglucosamine (GlcNAc) and GlcA saccharides. Most GlcA is then epimerised to 
iduronic acid. CS constitutes of N-acetylgalactosamine (GalNAc) and iduronic acid. GAG initiation 
and elongation occurs in the Golgi apparatus by the GAGosome. Sulphation patterns are modified 
on the mature GAG at the cell surface by specific enzymes.
4
 
   Sequences: synstatin (amino acids 82 to 130) have been shown to activate integrins during 
angiogenesis, GL is a cleavages site for ectodomain shedding, DRKE is proposed to affect 
oligomerisation and so is GXXXG. The RMKKK motif has been proposed as a nuclear localization 
signal and the EFYA motif facilitates PDZ-dependent bindings. 
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2 THE PRESENT STUDY 
Malignant mesothelioma is notoriously hard to diagnose and the prognosis is poor. The 
ancillary use of soluble biomarkers with conventional morphological examination could 
add accuracy and shorten time to final diagnosis. One possible biomarker, syndecan-1, is 
involved in the drive and progression of many cancers, but information about its effects 
and role in malignant mesothelioma is sparse. A better understanding of this 
proteoglycan in malignant mesothelioma might lead to increased options for treatment 
in the future. 
 
2.1  AIMS 
The overall aim of this thesis focuses on the diagnostic accuracy of soluble biomarkers 
and the molecular machinery governed by syndecan-1. This thesis is based on four 
studies with specific aims as follows: 
 
 Aim paper I: to combine established and novel biomarkers in an interpretation 
algorithm to increase the accuracy of mesothelioma diagnosis. 
 Aim paper II: to discover new soluble diagnostic biomarkers for malignant 
mesothelioma. 
 Aim paper III: to characterise mesenchymal tumours cell adhesion, migration 
and motility in regard to specific syndecan-1 domains. 
 Aim paper IV: to investigate the global gene change in a mesothelioma cell line 
after syndecan-1 overexpression and silencing. 
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3 REMARKS ON METHODOLOGY  
The following is a short discussion on methods and statistics involved in all the four 
papers. Methods exclusive for paper I and paper II are described under DIAGNOSTICS, 
while paper III and paper IV methods are described under SYNDECAN-1. For in-depth 
details please see the individual papers. 
 
3.1  DIAGNOSTICS 
3.1.1 Patient material and study designs 
Large enough patient cohorts, representative control groups and external validation are 
crucial elements in the design of biomarker studies306-308. Pleural effusions collected 
from patients by thoracocentesis were used in the translational part of this thesis work. 
The internal material in paper I was collected at the Department of Pathology and 
Cytology, Karolinska University Hospital in Huddinge, Sweden, and used for model 
generation. The external material was collected at the Medical Faculty of Eskisehir, 
Department of Chest Diseases, Turkey and was used for validation. Both the internal 
and the external material were collected in a prospective and consecutive way. This 
leads to control groups that are more representative of a clinical setting. The inclusion 
criteria for the internal material were strict, including only definite diagnoses and 
patients with long follow-up. This is important so that the model building is not 
undermined due to erroneously classified patients. However, the internal material was 
enriched for mesothelioma patients and hyaluronan had in some cases been included in 
the diagnostic work-up (although all diagnoses were verified with at least one 
independent method such as immunohistochemistry and/or EM). Therefore the internal 
material could have introduced biases. However, external validation on a large 
representative material safeguards final conclusions. 
 As evident from an extensive immunohistochemistry verification of a subgroup of 
patients from the external material it needs to be stated that the initial diagnoses were 
not 100 per cent accurate (see supplementary table S2, in paper I) – something that 
cannot be expected of any material, but needs to be kept in mind. 
 In paper II all material, both for initial proteome screening and validation, was from 
the Turkish sample collection. The validation sample in paper II were composed by 
randomly selecting similar numbers of mesothelioma patients and control patients 
resulting in a heterogeneous control group with the main differential diagnoses 
represented. 
 
3.1.2 Integrity of the analyte 
There are important discussions about which type of sample to analyse and how to 
acquire and store the material before analysis309,310. When whole blood is collected the 
first step is often to eliminate erythrocytes and other cells. The acellular plasma is left to 
coagulate and a fibrin rich precipitate can be eliminated through a simple centrifugation 
step; what remains is serum. This loss of material (the coagulate) has been shown to 
compromise the analysis of some biomarkers220,221 while not effecting others220. In our 
diagnostic studies (paper I and paper II) we use pleural effusions, which are thought to 
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resemble serum in their protein composition, and furthermore display a similar 
coagulative precipitate. The effusion is normally not treated to prevent coagulation and 
possible losses through fibrin precipitation cannot be excluded. Samples were frozen at 
-20°C or -80°C and care was taken to keep the number of freeze-thaw cycles to a 
minimum. No degradation of measured molecules was evident over time when plotting 
year of collection and biomarker expression values (data not shown). 
 A pleural effusion is often the first symptom of a malignant mesothelioma and needs 
to be drained. This results in samples available for analysis early in the process. 
Additionally, some of the effusion content will have been produced by the 
mesothelioma cells. There is a close proximity to the pleural tumours and a higher 
concentration (often ten to a hundred times higher) of measured molecules compared 
to serum151,153,155 meaning that rare proteins are more likely to be measurable. The 
closed pleural space is also less affected by elimination via organs outside of that 
circulation (e.g. hyaluronan degradation by the liver153 or mesothelin elimination via the 
kidneys155) and mixing of fluids from other body compartments. 
 
3.1.3 Measurement of biomarker levels and related biostatistics 
3.1.3.1 Enzyme linked immune-sorbent assay 
The main method to measure protein and hyaluronan levels in paper I, as well as 
validating biomarkers candidates in paper II, was enzyme linked immune-sorbent assay 
(ELISA) based. ELISA is a rather inexpensive technique with semi-high-throughput.  
 Since ELISA techniques utilises antibodies (in the case of hyaluronan it was a 
hyaluronan-binding protein), it also inherits all the caveats of the antibody field. Due to 
antibody differences there can be a large variance between different ELISA-kits using 
different antibody clones. This is exemplified by the development of the N-
ERC/mesothelin ELISA157,159, but the importance of choosing a suitable ELISA-kit is also 
evident for other proteins226. 
 Hyaluronan is historically often measured by ion suppression HPLC, a technique that 
separates molecules due to differences in dissociation constant between anionic 
compounds. This technique is more exact but also more time consuming compared to 
an ELISA based assay. 
 
3.1.3.2 Western blot 
When determining established biomarker levels by ELISA in paper I, osteopontin did not 
discriminate a mesothelioma in our hands. To estimate osteopontin degradation we 
analysed a few mesothelioma patient effusions by Western blot. With correct 
antibodies, this technique shows the entire amount of a specific protein with possibility 
to distinguish eventual degradation. 
 
3.1.3.3 Statistical measures 
Logistic regression 
Logistic regression is a multivariate regression analysis that measures the relationship 
between a categorical dependent variable (e.g. disease group) and one or several 
continuous independent variables (e.g. protein levels). It will give a probability that one 
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or several proteins are associated with a certain patient group. This analysis was 
performed in paper I and paper II. 
 
Internal validation 
Internal validation refers to testing the validity of a generated model in the same sample 
from which the model was generated. Permutation methods such as bootstrapping and 
cross-validation may be used. These methods can thus be performed on data at hand, 
without further enrolment of patients or analysis of samples. However, it is not as 
informative on the generalizability of the model as if an external validation is conducted. 
Bootstrapping is used in paper I, and 7-fold cross validation is used in paper II (see 
section Multivariate analyses (paper II), under 3.1.3.4). 
 The bootstrapping technique creates a new dataset by randomly selecting patients 
from an existing dataset with replacement. Patients can thus be selected more than 
once. The created dataset is yet again used to assess a biomarker or model and the 
results might vary from the first assessment. It is common to repeat this procedure at 
least a thousand times. The average model is then reported. 
 
Receiver operating characteristic (paper I and paper II) 
One way to describe the diagnostic capability of a biomarker is to plot its true positive 
rate (sensitivity) on the y-axis against its false positives rate (100 per cent minus 
specificity) on the x-axis. This results in a receiver operating characteristic (ROC) curve, 
and the area under this curve (AUC) is a measure of the biomarker’s overall accuracy. 
The highest possible AUC is 1, which corresponds to 100 per cent sensitivity and 100 per 
cent specificity. An AUC of 0 would be the perfect negative predictor. In contrast, an 
AUC of 0.5 indicates that the biomarker has no diagnostic value. 
 ROC curves are good to visualize a biomarker’s predictability and in most cases AUC 
values can be used to compare biomarkers. However, often the ROC does not tell the 
entire story311 and it will be especially difficult if the two curves cross. Therefore, novel 
measures have been suggested when comparing diagnostic predictability of 
biomarkers312,313. 
 
Novel measures (paper I) 
Calibration slopes: It is important to evaluate the correlation between the observed risk 
and the predicted risk. If a new biomarker or model was perfect, then these risks would 
be the same and the calibration slope would overlap completely with the ideal slope. 
Deviations of calibration from the ideal can suggest which risks a model classifies better. 
For example, it can be discerned that a model is better at classifying individuals with 
high risk of having a disease compared to those with a low risk. For an example see 
figure 5c and figure 5d in paper I. 
 
Net reclassification improvement: Diagnostic improvement by a biomarker or a model 
does not necessarily translate into significant changes in AUC. Net reclassification 
improvement tests a biomarker on how well it classifies the patients with and without 
the diagnosis separately. If adding a biomarker leads to more patients being classified 
correctly, then this is an improvement in reclassification. If fewer patients are classified 
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correctly with the novel measure, then that indicates worse reclassification. The sum of 
these changes is the net reclassification improvement.  
 
Integrated discrimination improvement and discrimination slope: The integrated 
discrimination improvement is a continuation of the net reclassification improvement, 
where net reclassification is measured over all possible cut-offs. This is equivalent to the 
change in discrimination slopes. The discrimination slopes are calculated as the 
difference in the means from the disease group and the control group (see figure 6 in 
paper I). 
 
These novel measures have been proposed as a complement and to give more 
diagnostic information than conventional measures of performance312,313. 
 
3.1.3.4 Proteomics 
Identification and quantification of proteins 
In a discovery study, such as the one described in paper II, mass spectrometry (MS) is a 
powerful tool to identify proteins. MS based proteomics was basically used to weigh 
peptides for identification and from them deduce information about proteins. By 
inducing a charge (proton) to the peptide, they can be moved by electric fields, 
separated by mass and detected. Using this information, the peptide mass can be 
measured and by including a peptide fragmentation step, the peptide sequence can be 
identified. From the identified peptides, proteins can be inferred – all this without using 
antibodies. 
 By measuring patient material, MS has long been thought to identify biomarkers for 
all conceivable diseases, but has not yet delivered to the hoped extent314. This is partly 
due to the high level of complexity of biological material as well as biological and 
technical variation resulting in a small overlap of identified proteins between analysed 
samples. Furthermore, one of the most studied materials – serum – is particularly hard 
to analyse due to its dynamic range of proteins. In serum, one protein can be present in 
femtomolar while another is present in micromolar. The dynamic range of human serum 
is believed to stretch over more than 14 magnitudes315. Even experienced MS 
laboratories have difficulties to span this dynamic range. The problem is that highly 
abundant proteins will mask the presence of low abundant proteins, which will be lost 
for analysis. Pleural effusions, as mentioned, are a similar to serum in composition and 
therefore offer the same challenge. 
 
Sample pre-treatment for proteomics 
In the discovery phase of paper II we selected homogenous patient groups with regards 
to age and phenotype of mesothelioma and controls (only lung adenocarcinomas and 
pleurisy). We furthermore excluded patients with known systemic diseases (such as 
diabetes mellitus and rheumatoid arthritis) or collision tumours. These steps were 
performed to reduce inter-patient variance. All pleural effusions were passed through a 
multi removal affinity system column (MARS-14). The MARS-14 column has antibodies 
directed against the human serums 14 most abundant proteins. These 14 proteins 
correspond to more than 90 per cent of the entire protein content of human serum316. 
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Affinity removal reduces the dynamic range, hopefully enabling the detection of low 
abundant disease-specific proteins. There is however, a risk that this step removes a 
possible mesothelioma biomarker if it shares binding site with any of the antibodies or is 
sequestered by one of the removed proteins. 
 
Samples were digested using trypsin, so the resulting samples contained peptides rather 
than proteins. To analyse peptides for protein identifications on a mass spectrometer is 
called shotgun proteomics, or bottom-up proteomics. Some of the advantages of 
working with peptides are that they more often result in clearer spectra. Also, even 
though some proteins are highly hydrophobic, they will still result in some hydrophilic 
peptides – this is important for sequential steps in our workflow. One of the drawbacks 
with peptide-centric shotgun proteomics is that several isoforms can contribute with 
indistinguishable peptides, making it impossible to resolve some protein isoforms 
(protein inference)317. Only unique/proteotypic peptides in the data set were used for 
quantification of a protein group in paper II. 
 
We used a relative quantification method called isobaric tag for relative and absolute 
quantification (iTRAQ). The iTRAQ mass tags label primary amines in peptides and 
proteins. The isobaric in iTRAQ means that all the different iTRAQ-labels have the same 
mass due to a variable region of the molecule. So a tagged peptide from one sample still 
have the same mass as the same peptide from a different sample tagged with another 
iTRAQ-label. At dissociation in MS/MS each iTRAQ-label produces a different reporter-
ion with a unique mass, giving relative quantifiable data from each individual sample. 
Labelling samples and pooling them reduce technical variance in following steps. In 
paper II we used two 8-plex iTRAQ-labels (i.e. we could label and pool 14 samples when 
one mass tag from each plex was used to create an internal standard to link the two 
resulting pools). This means that the number of samples is low; however the number of 
identified peptides that are common between samples will increase since 7 samples are 
quantified from a single peptide.  
 There are similar ways to label samples for pooling, with comparable pros and cons. 
Another option could be to screen samples label-free. Such measures of precursor ion 
intensity in the first MS spectra has been described as a sensitive method for estimating 
low abundant biomarkers318. However, the number of identified proteins would 
decrease. 
 
Another obstacle to overcome when screening the proteome is the complexity of 
biological samples. In paper II we were able to reduce the complexity by several 
fractionation steps. The most rigorous fractionation was achieved by ultra-narrow 
isoelectric focusing using an immobilized pH gradient (IEF-IPG)319. In brief, the samples 
are run on a gel-strip which has a pH gradient stretching from 4.0 to 4.25 (the range 
used in paper II). The peptides will migrate until they reach their isoelectric point where 
the net charge of the peptide is zero. Peptides with an isoelectric point outside this 
gradient will be lost to analysis and thereby the complexity is reduced. Here is another 
advantage of working with peptides, not only are they soluble at this step, but even in 
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this narrow pH range are the majority of all proteins are represented by at least one 
peptide. So, after reducing complexity, this method still retains the possibility to identify 
most proteins. Prior to the IEF run, we had performed a theoretical in silico digestion of 
known mesothelioma biomarkers so that we knew that the selected pH range would 
contain peptides of interest. The gel-strip is then physically fractionated into 72 parts; 
peptides from each are extracted and further fractionated on a nano-liquid 
chromatograph (nLC) for increased proteome coverage.  
 
Mass spectrometry  
For paper II we used the LTQ-Orbitrap Velos mass spectrometer, which is a hybrid 
instrument composed of a linear ion-trap and an Orbitrap. The peptides were charged 
by electron spray ionisation. Only peptides with charge Z ≥ +2 were considered for 
fragmentation since trypsin cleaves after arginine and lysine residues, which creates one 
positive charge at the N-terminus in addition to arginine and lysine on the C-terminus. 
Five precursors were selected for collision induced dissociation (CID) and higher-energy 
collisional dissociation (HCD) and then analysed in the linear ion-trap quadrupole and 
Orbitrap, sequentially. With its hybrid system the LTQ-Orbitrap has quickly established 
itself as the gold standard for proteome research today, allowing for a broader dynamic 
range and highly accurate mass measurements. Furthermore, the LTQ-Orbitrap is 
suitable for iTRAQ-ion dissociation and quantification since it is possible to fragment 
precursors by HCD and then analyse low mass range fragments in the Orbitrap320. 
 
Data mining 
For each analysis, there is an inverted relationship between data size and ambiguity of 
the results. This means that when the gigabytes of acquired MS/MS spectra are boiled 
down to a manageable list of identified proteins the uncertainty has increased due to 
inherent uncertainties in every step along the way. 
 
The scan speed of the mass spectrometer decides the amount of spectra actually 
acquired and algorithms match these spectra to amino acid sequences in a database. 
There are different algorithms for this purpose, with some leeway allowing specific 
amino acid modifications and missed cleavage sites. A database is preferably a non-
redundant, curated and frequently updated database. This means that there are no 
multiple entries per gene/protein, which make the search more efficient. Obsolete and 
false sequences/entries are deleted and it is up to date with high quality sequences. 
Non-existing sequences in the database will not be mapped. The UniProtKB/Swiss-Prot 
database was used in paper II, which is a non-redundant, manual annotation, high-
quality (i.e. frequently reviewed and curated) database. 
 
False discovery rate (FDR) was evaluated in paper II by the SEQUEST and Percolator 
algorithms using a target decoy database approach. A decoy database contains 
nonsense sequences (usually reversed protein sequences) that the spectra are searched 
against. All hits in the decoy database are considered false positives and the amount is 
used to estimate the FDR for that search in the target database. In paper II FDR was not 
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allowed to be more than 5 per cent (i.e. with those settings not more than 5 out of 100 
peptides identifications would be false discoveries). 
 
Multivariate analyses (paper II) 
Principal component analysis (PCA) was performed to see sample distributions related to 
protein expression in a multivariate unsupervised way. By using all analysed protein levels, 
a PCA show similarities and dissimilarities between samples. In this way PCA can give an 
overview of the data, showing possible clusters and outliers. Values were unit variance 
scaled and mean centred to assume the same importance of each protein irrespective of 
relative abundance and variance between samples. Furthermore, log2-transformion was 
performed to give equal weight to up and down regulation of proteins. 
  
Orthogonal partial least squares discriminant analysis (OPLS-DA) is a supervised linear 
multivariate model, in which multiple proteins can be joined in a model to differentiate 
between sample groups. OPLS-DA gives a linear model that can predict new samples and 
identify related/dependent variables (proteins). The proteins that best explain the 
variance between selected groups are interpreted from the model.  
 Seven-fold cross-validation (CV) was performed on each OPLS-DA model. With this 
internal validation method, 1/7 of the samples is excluded from the model and predicted 
by a model created from the remaining 6/7. The cross-validation is repeated until all 
samples had been left out once. In this manner it is possible to calculate the significance 
of the built model by an ANOVA on the predicted scores from the CV. 
  
Univariate analysis (paper I) 
A normal t-test will quickly run into problems when applied to too many comparisons at 
once. This is becoming increasingly common in today’s medical research when the 
number of simultaneous analyses increase. The conventional level of p < 0.05, when 
applied to thousands of tests will inevitably lead to an increasing number of false positives 
(i.e. falsely rejecting the null-hypothesis). In such a situation it is needed to estimate the 
FDR. In paper II significant analysis of microarrays (SAM) was used for differentially 
expressed proteins between groups. In this method, the data is repeatedly permutated 
and used to assess if a protein is significantly regulated in the disease group. While 
performing multiple non-parametric t-tests, SAM also calculates and reports the FDR as q-
values (corrected p-values). 
 
3.2  SYNDECAN-1 
3.2.1 Cell cultures 
In paper III and paper IV, we used the STAV-AB malignant mesothelioma cell line, which 
grows with an epithelioid phenotype. The B6FS fibrosarcoma cell line used in paper III 
displays a more fibroblast-like morphology. These cell lines are suitable for syndecan-1 
induction studies since their endogenous level of syndecan-1 is low. Clones with stable 
syndecan-1 transfection were established from both cell lines by geneticin selection. 
Transfection rate was lower in the STAV-AB cells compared to the B6FS cell line. 
Additionally, it was only possible to establish sub-clones with high or low syndecan-1 
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expression from the B6FS cells. These sub-clones retained their respective syndecan-1 
levels in later passages. 
 
3.2.2 Syndecan-1 constructs and syndecan-1 silencing 
In paper III, several constructs of syndecan-1 were used to evaluate the effects of 
different core protein segments on cell adhesion and motility. Cells were transfected 
with three truncated syndecan-1 versions either mimicking syndecan-1 shedding by i) 
lacking the entire ectodomain (construct 77), ii) lacking most of the ectodomain with the 
exception for the DRKE sequence (construct 78), or alternatively iii) only containing the 
penta-peptide RMKKK that is close to the plasma membrane on the cytoplasmic side. 
The 77 and 78 constructs resembles remaining syndecan-1 after shedding, and the DRKE 
sequence is thought to be important for oligomerisation. The RMKKK oligopeptide, on 
the other hand, is a proposed nuclear localization signal267. An additional construct 
contained the entire, full-length syndecan-1. All four constructs were EGFP tagged and 
the control construct carried an EGFP protein only. Overexpression of proteoglycans 
might lead to aberrant GAG synthesis due to exhaustion of the GAGosome, which will 
have to be kept in mind during result interpretation. 
 
STAV-AB cells stably overexpressing syndecan-1, together with STAV-AB cells silenced 
for syndecan-1 were analysed for their total mRNA content in paper IV. Silencing was 
transiently achieved by a cocktail of three siRNA constructs. A scrambled siRNA 
sequence was used as a negative control. Successful overexpression and silencing of 
syndecan-1 was evaluated both on mRNA and protein level using qPCR and fluorescent 
cell activated sorting (FACS), respectively. 
 
3.2.3 Adhesion and motility (paper III) 
3.2.3.1 Cell adhesion assay 
To evaluate the rate of cell adhesion in paper III, the cells were allowed to adhere to the 
bottom of a 96-well plate for 5 minutes. After washing, adherent cells were lysed and 
their number was indirectly measured by staining the released DNA with CyQUANT® dye 
and reading as fluorescence. The acquired measure focuses on early adhesion 
responses. 
 
3.2.3.2 Random movement assay 
Sub-confluent cells were grown on glass bottom culture plates and time-laps imaging 
was conducted with an interval of 15 minutes for 16 hours. Cell movements were 
classified in two ways: total distance and final displacement. The first indicates the 
length the cells have moved away from the start position, while the latter indicates the 
total distance the cells have traversed regardless of direction. 
 
3.2.3.3 Wound healing assay 
Migration was evaluated by the ability of cells to close an artificial wound in their 
confluent population. The wound was afflicted by scratching the cell layer with a sterile 
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pipette tip and healing was measured with image processing software. The distance 
between the leading edges of the wound was measured at six random points at three, 6 
and 12 hours. 
 
3.2.3.4 Chemotaxis assay 
Chemotactic migration was assessed using a 24-Transwell plate, where cells were 
seeded in serum-free medium in the upper compartment and allowed to migrate down 
through micropores towards serum supplemented medium. The number of migrated 
cells was then measured by collecting the cells that had migrated through and 
measuring their DNA content with CyQUANT® dye. 
 
3.2.4 Transcriptomics 
The Affymetrix GeneChip® Human Gene 1.0 ST microarray was used to evaluate the 
global gene expression of STAV-AB cells in paper III and paper IV. This gene chip contain 
probes mapping the entire length of each gene analysed. In this manner splice variants 
can be discerned, and in combination with random primers for cDNA synthesis, mRNA 3’ 
degradation bias is partly avoided. 
 
To focus the global gene analysis in paper III, we used the gene ontology (GO) 
annotations adhesion, migration and chemotaxis. These identified genes associated with 
these cellular functions. There are however, misannotations and positive literature bias 
(see following section) that might cloud the interpretation of the results. 
 
3.2.4.1 Gene set enrichment, network enrichment and pathway analysis (paper IV) 
Characterizing differentially expressed (DE) genes as whole groups, sub-groups, or 
individually can be difficult. Generally, genes with altered expression (altered gene sets; 
AGS) are matched to known functional groups (e.g. GO terms; i.e. functional gene sets; 
FGS) and in classical gene set enrichment analysis (GSEA) a specific function will be 
ascribed to the AGS if it shares an enriched fraction of genes with a specific FGS (i.e. 
contains more than can be assumed by random chance alone). This analysis, however, 
only regards DE genes that are assigned to any FGS, while disregarding known functional 
links within the analysed AGS or between the AGS and FGS. 
  
Pathway analysis (ingenuity pathway analyser; IPA), also reveals associations between 
sets of altered genes and known pathways or other functional sets, but the analysis is 
applied to so called networks. They are compact clusters or modules of genes tightly 
interconnected in the global network and enriched in DE genes. Then these networks are 
characterized as separate units. Thus, IPA analysis employs only such DE genes that can be 
grouped in modules, which might not always be the case. 
 The novel network enrichment analysis (NEA) works in similar manner to conventional 
GSEA, with the difference that NEA considers also links between genes of AGS and FGS in 
the global network. NEA was shown to increase the sensitivity (statistical power) of 
associating AGS with FGS compared to GSEA321. In distinction from IPA, NEA does not 
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expect any ready modules in the network and uses all AGS genes that have direct network 
links to genes of known FGS.  
 
GSEA, IPA and NEA employ network links derived from literature searches and high-
throughput data analysis for each gene/protein, both inside and outside of canonical 
pathways and GO terms. This information might be too focused on published interactions 
that are proven to exist, while negative experimental results largely remain unpublished 
(the positive literature bias). This is a generic feature of all the three methods. 
 
3.2.4.2 Verification and validation of transcriptomic findings 
In paper IV, a set of identified DE genes were verified on mRNA level using qPCR or 
validated on protein level using a Western blot based proteome profiler assay. 
Verification at the mRNA level indicates the integrity of the microarray results, while 
validation at the protein level will strengthen the conclusions about syndecan-1’s 
postulated effect on cell behaviour. 
 
3.2.5 Functional assays (paper IV) 
The effect of syndecan-1 silencing on cell proliferation was evaluated by the viability 
WST-1 assay. WST-1 is a tetrazolium salt that acts as a substrate for many mitochondrial 
enzymes. The generated products colour the cell media red, and absorption is measured 
at 450 nanometre as an indirect correlate to cell number. 
 
Effect of syndecan-1 silencing on mesothelioma cell proliferation was further assessed 
by analysing cell cycle distribution. Syndecan-1 silenced cells and controls were fixed and 
partly permeabilized using cold ethanol. Total nucleic acid content was stained with 
propidium iodide (PI) after elimination of RNA by RNase pre-treatment. Cells were 
analysed by FACS. Cells in G0/G1 have a certain intensity of PI, visible as a peak and 
corresponding to their amount of DNA. Cells with double intensity of PI are presumed to 
be in G2/M phase and all cells in-between these two peaks should then correspond to 
cells in S-phase. 
 
To assess apoptosis, non-fixed syndecan-1 silenced cells were stained with PI and FITC 
conjugated Annexin-V. PI enters cells with severely damaged plasma membrane 
(necrotic). Annexin-V binds phosphatidylserine, a phospholipid that normally faces the 
cytoplasm, but in early apoptosis becomes visible on the surface of the cell. By FACS 
analysis we could thereby describe cell populations in early apoptosis as well as 
distinguish the apoptotic and necrotic fractions. However, late stages of cell death are 
not distinguishable using this method. Furthermore, cell stress can give reversible 
Annexin-V reactivity, possibly resulting in false positives322. 
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4 RESULTS AND DISCUSSION 
 
4.1  PAPER I: PLEURAL EFFUSION BIOMARKERS FOR DIAGNOSIS OF MALIGNANT 
MESOTHELIOMA 
 
The diagnosis of a malignant mesothelioma is difficult, and the additional measurement 
of soluble biomarker levels could be advantageous. Several studies have tried to 
combine soluble biomarkers to increase the diagnostic accuracy, however, few have 
succeeded136. 
 
In paper I we evaluated 7 soluble biomarkers, 4 well-known in addition to three novel 
biomarkers. The 4 more established markers were hyaluronan, two proteolytically 
generated parts of mesothelin (the N-terminal N-ERC/mesothelin and the C-terminal C-
ERC/mesothelin) as well as osteopontin. The three additional biomarkers were 
syndecan-1, syndecan-2 and thioredoxin. Levels were assessed on an internal sample of 
190 patient effusions. Log10-transformation was used since it generated distribution 
more closely resembling normal distribution. By using bootstrapping it was clear that 
hyaluronan and N-ERC/mesothelin were the strongest predictors of a malignant 
mesothelioma (ROC curves for each of the 7 biomarkers can be seen figure X in paper I). 
In paper I ROC curves are calculated to estimate diagnostic utility. Analysis of a 
combinations incremental value was assessed using calibration slopes, net 
reclassification improvement, integrated discriminatory improvement and 
discrimination slopes as suggested by a recent study313. 
 Syndecan-1 is associated with epithelial cells and the ectodomain is solubilised by 
shedding, and were detectable in the pleural effusions. Results in paper I indicates that 
syndecan-1 could function as a general carcinoma marker. Osteopontin did not 
discriminate a mesothelioma in this study. The protein was shown to be only marginally 
degraded, and was disregarded as a possible effusion biomarker for malignant 
mesothelioma. 
 
Several groups have attempted to combine established soluble biomarkers such as 
hyaluronan and mesothelin without success153,158,160,220. Most comparable to paper I is 
the study by Grigoriu et al. from 2009 that attempted a logistic regression based model 
of hyaluronan and mesothelin. Their conclusion was that there was no gain from a 
combinatorial approach153. 
 One of the main reasons why a direct joining of these two markers by logistic 
regression will fail is the phenomenon of linear separation. This means that one 
biomarker on its own separate the disease group of interest, from control groups to 
such an extent that another marker will not identify additional patients. Combination in 
such a scenario could even result in decreased predictability. 
 So, as expected, in paper I combination of hyaluronan and N-ERC/mesothelin by 
logistic regression did not yield better predictions with the entire sample material 
included. However, inclusion of a cut-off based step to select patients with moderate 
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expression led to avoidance of linear separation. Ascribing an individual cut-off value 
that defined 100 per cent specificity for each biomarker before applying logistic 
regression to all patients bellow, led to a significantly increased accuracy over single 
biomarker analysis. P-values ascribing a probability of having a mesothelioma could then 
be calculated by incorporating log10 values for each biomarker into a logistic regression 
model. Probability ranged from 0 to 1, where 0 is no likelihood of having a 
mesothelioma and 1 is 100 per cent likelihood of having a mesothelioma. Besides, all 
patients with an initial expression level for either of the two biomarkers above their cut-
off value automatically resulted in a p-value of 1. 
 Introduction of a cut-off value to avoid linear separation of high expressing 
mesotheliomas might have been the most significant contributing factor in enabling 
combination of hyaluronan and N-ERC/mesothelin. However, when comparing to the 
study by Grigoriu et al., additional differences are evident. Most notably, they utilized 
the C-terminal part of mesothelin (as measured by the MesoMark™-kit) and only had 
pleural effusions from a limited number of patients (20 mesotheliomas and 29 
controls)153.  
 A crucial part of our study involved a large external validation. When applying the 
two-step model on the external validation material there was shrinkage of 
predictability. There was still, however, an advantage in combining both biomarkers 
over single analyses.  
 The reduced performance upon validation is expected and will partly be due to 
differences in the study populations: for example, in the external material, less 
laboratory support for the diagnosis might lead to the inclusion of some more uncertain 
diagnoses. Furthermore, with a different source of exposure, the Turkish material had a 
larger proportion of women with mesothelioma (65 per cent compared to 11 per cent in 
the internal material) and to some extent it also had a different setup of diagnoses in 
the control group. Additional biases, such as batch effects, seem less likely but could 
imply a difference as well. Accordingly, a model will almost always perform best on the 
material it was created in, and therefore it is of utmost importance to include a proper 
external validation.  
 
This study furthermore indicates that the N-ERC/mesothelin is to be preferred over C-
ERC/mesothelin when measuring mesothelin to aid mesothelioma diagnosis. The two 
mesothelin entities had similar a discriminatory capacity, however, N-ERC/mesothelin 
was marginally better, and more strikingly, was selected over C-ERC/mesothelin in all 
bootstrap iterations. 
 
This study shows that a combination of hyaluronan and N-ERC/mesothelin was 
achievable after avoiding linear separation. In this way the sensitivity for a malignant 
mesothelioma was significantly increased. Still, a fraction of the mesothelioma patients 
go undiagnosed. 
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4.2  PAPER II: PROTEOME SCREENING IDENTIFIES GALECTIN-1 AS A NEGATIVE 
PREDICTOR FOR MALIGNANT MESOTHELIOMA IN PLEURAL EFFUSIONS 
 
The most established biomarker combinations will not identify all malignant 
mesotheliomas (paper I), it is therefore an urgent need for new soluble biomarkers to 
aid diagnosis135,136. 
 
In paper II we initiated a discovery phase were we screened the proteome of pleural 
effusions from 6 epithelioid mesotheliomas, 6 metastatic lung adenocarcinomas and 
two pools of effusions caused by benign conditions. Sample pre-processing included 
affinity removal of abundant serum proteins, iTRAQ mass labelling and ultra-narrow IEF 
fractionation. Two iTRAQ 8-plexes were used, and when analysed with nLC-ESI-MS/MS, 
1184 proteins were detected in the first iTRAQ pool and 569 proteins were detected in 
the second iTRAQ pool. The overlap between the different pools was 382 proteins. The 
evaluation with biostatistics and bioinformatics focused mostly on the overlapping 
proteins. 
 Principal component analysis showed a relatively high homogeneity between 
samples. OPLS-DA supervised clustering and model building identified 37 proteins in a 
model with moderate discriminatory capacity of a mesothelioma from a lung 
adenocarcinoma. SAM analysis identified differentially regulated proteins comparing 
mesothelioma and lung cancer effusions, while assessing their q-values. It is likely that 
the influence of biological variance between individuals, and the small number of 
patients is the cause of rather high q-values (> 20 per cent) found in this study. 
Nevertheless, several proteins known to be involved in mesothelioma pathobiology and 
or diagnosis were identified, strengthening our study design. 
 
Candidate biomarkers were chosen based on these analyses and on biological 
interactions and information about the identified proteins. These candidates were 
further validated on a larger population of patient effusions. Validation included 
controls with a composition encountered in the clinical setting. It was unfortunately not 
uncommon that initial MS findings and ELISA validation did not correlate. This could be 
due to the protein inference problem with shotgun proteomics or due to varying 
antibody specificities of the ELISA assays compared to antibody-free MS analysis. 
 
Findings in paper II include kallistatin, an inhibitor of both TNF-α and NFkB signalling323. 
In our MS based screening, kallistatin was lower in mesotheliomas than controls, which 
is a cross-validation of another recent study on the same topic244. Proteins involved in 
cells ROS response were upregulated in the mesothelioma patients (superoxide 
dismutase-2 and catalase).  
 Individual patient pathway analyses indicate well-known mesothelioma and cancer 
hubs (ERK1/2, EGFR and NFkB). Interestingly, ezrin and moesin were downregulated in 
pleural effusions from some mesothelioma patients (data not shown). These proteins 
are closely related and share several functions with merlin. They all interact with CD44 
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and suppress cell proliferation324. However, due to few patients and high variance, it is 
hard to draw any conclusions from this analysis. 
 
One of the major findings includes the excellent discrimination of mesotheliomas and 
adenocarcinomas by galectin-1. Galectin-1 is a matricellular protein that has been 
shown to deactivate T-cells by regulating T-cell apoptosis325. Galectin-1 enables 
carcinoma cells to evade the immune system and invade surrounding tissue and 
metastasise326. In agreement with this, galectin-1 was highly expressed in the metastatic 
adenocarcinomas in paper II. The difference between mesothelioma cells and benign 
reactive mesothelium is less pronounced and will probably not be enough for 
discrimination between these two conditions (see figure 4 in paper II). 
 Several proteins showed prognostic trends in the mesotheliomas, including galectin-
1 (p-value = 0.17) where high values were associated with shorter survival. However, 
aldo-keto reductase 1B10 was the only validated prognostic candidate to be considered 
significant (p-value = 0.01; see figure 5 in paper II). High levels of aldo-keto reductase 
1B10 predicted shorter survival. Aldo-keto reductase 1B10 is an aldose reductase that 
reduces certain aldehydes327. Interestingly, aldo-keto reductase 1B10 expressions seem 
to be EGF and AP1 dependent328 and has been linked to carboplatin and gemcitabine 
resistance in bladder cancer329. Information about tumour stage was not available in 
paper II, so a more biological association of aldo-keto reductase 1B10 with survival time 
could not be properly assessed. 
 
There is a need for novel mesothelioma biomarkers today. Screening the effusion 
proteome from patients identified thousands of proteins. To filter out and identify 
possible biomarkers is a difficult task, however, in paper II we present several promising 
candidates including galectin-1 and aldo-keto reductase 1B10. 
 
4.3  PAPER III: SPECIFIC SYNDECAN-1 DOMAINS REGULATE MESENCHYMAL 
TUMOR CELL ADHESION, MOTILITY AND MIGRATION 
 
A better understanding of the motility of malignant mesenchymal cells could help to 
explain the invasive nature of these tumours. 
 
In paper III we focus on the possible biomarker syndecan-1, in regard to how different 
domains affect cell adhesion, motility and migration. We transfected various constructs 
of syndecan-1 into mesothelioma and fibrosarcoma cells while monitoring adhesion and 
motility read-outs from wound-healing, chemotaxis and live cell imaging. Additionally, 
we performed a transcriptomics analysis after syndecan-1 overexpression with focus on 
gene-changes especially affecting adhesion, migration and/or chemotaxis. 
 
Overexpression of full-length syndecan-1 led to enhanced adhesion in the fibrosarcoma 
cell line in a dose-dependent manner. Overexpression decreased serum induced 
migration in both cell types, possibly also syndecan-1 dose-dependent. 
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 As measured by time-lapse microscopy, syndecan-1 decreased the final displacement 
of fibrosarcoma cells, while not affecting the total distance of their migrated path. So, in 
fibrosarcoma cells, overexpression of syndecan-1 decreased directional migration, but 
not total movement. These data indicates that overexpression of syndecan-1 in this 
fibrosarcoma cell line does not decrease motility, but induces adhesion and by doing so 
affects migration. Furthermore, in vitro wound-closure was impeded after transfection 
of full-length syndecan-1 in both cell lines. 
 
Constructs of different syndecan-1 domains showed that adhesion was largely achieved 
through the GAG containing ectodomain. The RMKKK construct decreased cell adhesion 
in the fibrosarcoma cell line. In the same cell line the 78 construct increased cell 
adhesion. Full-length syndecan-1 increased adhesion dose-dependently. In the B6FS cell 
line, the 78 construct also decreased final displacement, whilst the 77 construct did not. 
This indicates the importance of the juxtamembrane DRKE motif. However, all truncated 
constructs increased final displacement in the mesothelioma cell line. 
 Furthermore, all constructs, except RMKKK, decreased serum initiated cell migration 
in both cell lines. The RMKKK construct, only impaired chemotaxis of fibrosarcoma cells. 
All constructs seemed to slow down in vitro wound healing. 
 Deletion of RMKKK furthermore showed a loss of nuclear syndecan-1 (figure 6 in 
paper III), which is in line with earlier findings, where deletion of RMKKK decreased 
proliferation261. It can be suggested that the effects of the RMKKK construct on adhesion 
is linked to nuclear translocation of full-length syndeacan-1. It could be that the RMKKK 
peptide out-competes syndecan-1 for nuclear shuttling, and thereby affects 
proliferation and also adhesion. 
 
Measuring the global gene changes in the mesothelioma cell line after full-length 
syndecan-1 overexpression highlighted several interesting genes. MTSS1, one of the 
most upregulated genes, has been reported to suppress cancer migration330 while the 
most downregulated gene (SLAMF7) belongs to a family also affecting adhesion331. A 
large fraction of the deregulated genes were linked to adhesion, migration and 
chemotaxis (GO terms).  
 
These results indicate varying roles of different syndecan-1 domains as well as cell line 
specificity. Syndecan-1 seems to increase adhesion on the expense of cell motility and 
migration in the fibrosarcoma cell line. While in the mesothelioma cell line, adhesion is 
lost together with increased motility. However, the results are varying in effect and 
direction. It cannot be excluded that some of the observed effects are influenced by 
changes in the remaining syndecans (most likely syndecan-2 and syndecan-4), since the 
levels of the syndecan family members seem to include some extent of redundancy261. 
 Furthermore, migration is described as having a biphasic migration-velocity response 
to ECM adhesion284, where too much adhesion will reduce migration, as will too little 
adhesion. This needs to be taken into account when interpreting the results. 
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The findings presented in paper III indicate that mesenchymal cell motility is affected by 
various syndecan-1 domains in cell line specific patterns. 
 
4.4  PAPER IV: NOVEL GENES AND PATHWAYS MODULATED BY SYNDECAN-1: 
IMPLICATIONS FOR THE PROLIFERATION AND CELL-CYCLE REGULATION OF 
MALIGNANT MESOTHELIOMA CELLS 
 
The study in paper IV was designed to elucidate gene and pathway changes related to 
syndecan-1 in the malignant mesothelioma STAV-AB cell line. We modulated the levels 
of syndecan-1 by overexpression or silencing and then followed changes in the global 
gene expression. 
 
We know from previous studies that overexpression of syndecan-1 reduces proliferation 
of STAV-AB cells261. So we determined the effect of syndecan-1 silencing on proliferation 
and cell cycle distribution. It was evident that silencing of syndecan-1 decreased 
proliferation, as seen by reduced cell number and extended doubling time. 
Furthermore, cell cycle distribution was significant altered. 
 
Transcriptome analysis indicated a remarkable effect on the global gene expression 
after syndecan-1 modulation. The change was most pronounced in the syndecan-1 
overexpressing cells: at a cut-off of more or less than two folds differential expression, 
there were 1,124 DE genes in the syndecan-1 overexpressing cells and only 21 in the 
syndecan-1 silenced cells (q-value < 0.05). Lowering the threshold to one and a half 
times up- or downregulated increased these numbers to 2,389 and 103, respectively. 
Fourteen genes were affected by both silencing and overexpression of syndecan-1 (see 
table 1 in paper IV). 
 
We employed traditional GSEA and pathway analyses as well as a novel NEA approach 
to determine structure within this vast list of DE genes. Several transcripts encoding 
enzymes involved in heparan sulphate sulphation patterning (SULF1, SULT1B1 and 
SULT1E1) were significantly downregulated after syndecan-1 overexpression, which 
indicates a changed GAG profile of these cells. This could have effects on many GAG 
dependent cellular processes. 
 Genes regulated by syndecan-1 overexpression were involved in cell proliferation 
and cell cycle progression, cellular adhesion, migration and ECM organisation. 
Furthermore, pathways that belong to TGFβ signalling and growth factor signalling 
(PDGF, FGF, EGF and VEGF) were affected along with cytokine signalling in syndecan-1 
overexpressing cells. Several of these changes could be specific to the mesothelioma cell 
line used. 
 
DE genes in the syndecan-1 silenced cells were fewer. However, the pathways that they 
affected were still numerous. Pathway analysis show effects on cellular movement, cell 
death, growth and proliferation, cell-to-cell signalling and several other processes 
(figure 6 in paper IV). The fact that syndecan-1 silencing affected a much lower number 
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of genes could be explained by the initial low amount of endogenous syndecan-1 in 
these cells. 
 
Functions affected by syndecan-1 modulation showed strongest association with 
adhesion, motility, proliferation and cell cycle. Moreover, pathway analysis indicated a 
common effect on interleukin and growth factor signalling. NEA analysis of both 
syndecan-1 overexpressed and syndecan-1 silenced cells revealed an astounding effect 
on cell proliferation. Almost all analysed pathways linked to cell cycle were depleted 
after syndecan-1 overexpression and enriched after syndecan-1 silencing – asserting the 
role of this proteoglycan on proliferation. NEA moreover, identified mutual effects on 
several KEGG pathways (such as signalling by EGFR, pathways in cancer and VEGF 
signalling) and growth factor signalling. Hence, NEA confirmed many findings and also 
indicated effects on the vast majority of other pathways and cellular functions (figure 9 
in paper IV). 
 
In paper IV it is shown that syndecan-1 silencing hampers proliferation. Since a similar 
effect has been reported earlier for syndecan-1 overexpression261, it indicates that there 
might be an optimal amount of syndecan-1 to allow maximum proliferation in these 
mesothelioma cells. It might be a similar bell-shaped curve as is reported to exist 
between adhesion and migration. TGFβ2 is down regulated upon syndecan-1 
overexpression, and interestingly, it has been shown that TGFβ2 has an anti-
proliferative effect in mesothelioma cells by delaying syndecan-1 translocation to the 
nucleus332. 
 
Taken together paper IV shows a great impact of the level of syndecan-1 in this 
malignant mesothelioma cell line on the global gene expression, especially proliferation. 
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5 GENERAL CONCLUSIONS 
 
5.1  SUMMARY OF MAJOR FINDINGS  
 
Paper I: Combination of established mesothelioma biomarkers 
 Combination of biomarkers into a model was possible when a cut-off level was 
included to avoid linear separation. 
 Evaluating N-ERC/mesothelin instead of C-ERC/mesothelin in pleural effusions 
seems to be preferred. 
 The constructed two-step model, including hyaluronan and N-ERC/mesothelin, 
increased sensitivity for diagnosing a malignant mesothelioma in pleural effusions. 
Since pleural effusions are often the first symptom of a mesothelioma, this finding 
could aid diagnosis. 
 
Paper II: Proteome discovery of de novo biomarkers for malignant mesothelioma 
 More than a thousand proteins were identified in pleural effusions from 
mesothelioma patients and controls, with links to several interesting cancer 
associated pathways. 
 Galectin-1 is described for the first time as a strong negative predictor of malignant 
mesothelioma compared to metastatic adenocarcinomas. 
 Aldo-keto reductase 1B10 is described for the first time as a prognostic biomarker 
for malignant mesothelioma. 
 
Paper III: Syndecan-1 domains with varying influence on adhesion, migration and motility  
 Adhesion of mesenchymal tumour cells is negatively correlated to migration and 
altered following syndecan-1 overexpression.  
 Various parts of the core protein assert different effects; broadly it seems as though 
the ectodomain is more important for cell adhesion, while the transmembrane and 
cytoplasmic domain is enough to inhibit cell migration. However, these effects seem 
to be context dependent. 
 The novel nuclear localization signal RMKKK might be involved in mesenchymal 
tumour cells motility by decreasing the amount of full-length syndecan-1 
translocated to the nucleus. 
 
Paper IV: The influences of syndecan-1 on the transcriptome 
 Syndecan-1 levels of a malignant mesothelioma cell line greatly influenced the 
transcriptome.  
 Overexpression of syndecan-1 regulated genes involved in cell proliferation, 
adhesion and migration, which is in line with earlier findings. 
 Together, silencing of syndecan-1 and overexpression of syndecan-1 affected a 
multitude of cellular signalling pathways – most strikingly cell cycle networks. 
 Links to interleukin, growth factor and TGFβ signalling pathways and GAG 
modifications are identified. 
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5.2  FUTURE PERSPECTIVES 
 
Combination of biomarkers is an appealing way of reaching sufficient diagnostic 
accuracy to aid the morphological assessment of a malignant mesothelioma. However, 
combinatorial efforts have struggled. In paper I we describe the incremental value of 
hyaluronan and N-ERC/mesothelin, but in the future more biomarkers will have to be 
added to a growing panel. Such additions could include galectin-1 (paper II), fibulin-3 
and others.  
 If the panel reaches several tens, or hundreds, of proteins, then conventional ELISA 
techniques will most likely be impractical in the clinical routine. In paper II a model with 
37 variables showed moderate discrimination, and it would probably be beneficial to 
assess such a model using similar mass spectrometry based methods (e.g. multi reaction 
monitoring) or other multiplex assessment (e.g. Luminex® or SOMAmer technology). 
 
Validation studies of galectin-1 will be performed together with additional biomarkers 
that are able to separate malignant and benign cases. The finding of a possible 
prognostic role for aldo-keto reductase 1B10 might be of interest for treatment 
purposes. High levels of this enzyme can lead to chemo resistance and possibly explain 
shorter patient survival. There are specific aldo-keto reductase 1B10 inhibitors 
developed for the treatment of diabetes mellitus (e.g. Tolrestat) that could be given 
neoadjuvant to patients with high levels of the enzyme. This could sensitise these 
patients to chemostatic treatment, resulting in longer survival times. It is not 
uncommon that prognostic markers go forward to predict treatment. 
 
In both paper I and paper II, there is an interesting sub-group of patients suffering 
benign asbestos pleuritis. These patients have been exposed to asbestos and developed 
a chronic inflammation in the pleura, but not mesothelioma. This group has a high risk 
of developing this tumour and could be the key to identify early, sub-clinical markers for 
the disease. 
 It will, however, be in serum that such early markers will be evaluated. The pleural 
effusions might be the first symptom, but is still a sign of advanced disease. Also, in the 
case of assessing surrogate endpoints to show efficiency of treatment, serum markers 
will have to be developed. Some of these studies have already been undertaken in our 
laboratory. 
 
Syndecan-1’s effect on mesenchymal cell behaviour is not fully understood. The 
clarification of this proteoglycans role in cell migration and cancer invasion could be 
rewarding for combatting the disease. Paper III touches upon these questions, but more 
studies will have to be conducted. The multitude of gene changes described in paper IV 
furthermore elucidates and highlights syndecan-1’s role in mesothelioma adhesion, 
migration and cell proliferation. Based on paper III, paper IV and published research, 
syndecan-1 could be interesting to examine with focus on the EMT character of 
malignant mesothelioma. For example the role of TGFβ in mesothelioma cells 
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transdifferentiation and invasion. Findings in paper IV indicate several growth factors, 
cytokines and GAG modification that will be exciting to investigate. Moreover, the novel 
NEA method described seems to be a powerful tool for a holistic view on transcriptomic 
changes. 
 
Syndecan-1 is investigated in paper I as a biomarker for carcinomas and seems to carry 
diagnostic information. Syndecan-1 is furthermore identified in paper II as 
downregulated in mesothelioma effusions compared to effusions from lung cancers 
(however, with high q-values). These findings together with syndecan-1’s role in tumour 
cell adhesion, migration and proliferation (paper II and paper IV) makes this 
proteoglycan interesting to study further in mesenchymal tumours and especially in 
malignant mesothelioma. 
 
Final remarks 
As a whole, this is a translational thesis with diagnostic implications as well as 
experimental studies of syndecan-1-dependent cell behaviour. The outcomes include 
increased diagnostic sensitivity for a malignant mesothelioma, possible new biomarkers 
and an increased understanding of syndecan-1’s role in mesenchymal tumours. In the 
imminent future are studies to validate mesothelioma biomarker candidates and to 
follow-up molecular pathways regulated by syndecan-1. 
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